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Abstract 
Angiogenesis is one of the crucial steps in endogeneous repair mechanism. 
However, in injured spinal cord, this process is impaired at the developing cavity 
resulting in disrupted capillary network. This subsequently propagates a cyclic 
breakdown of the blood-spinal cord barrier (BSB) leading to a persistent inflammatory 
response and secondary degeneration. Vascular endothelial growth factor (VEGF) is 
well known as a potent stimulator of angiogenesis. Whilst VEGF can initiate 
angiogenesis, its presence alone is not always adequate for mature vessel formation. 
Platelet-derived growth factor (PDGF) which stimulates smooth muscle cell migration, 
is an important molecule in vessel stability and maturation. This prompted us to consider 
dual growth factor delivery into the injured spinal cord. Our hypothesis was that the co-
delivery would improve the intra-lesion angiogenesis and stabilise the BSB, which helps 
to reduce tissue hypoxia and slow down the infiltration of inflammatory cells.  
The first part of the study was to set up an traumatic spinal injury (SCI) model 
called lateral hemisection. We also examined the effect of hyperbaric oxygen treatment 
(HBOT), which is known to promote angiogenesis and reduce tissue hypoxia, on lesion 
size and inflammatory cells in the hemisection SCI model. The treatment was applied in 
a hyberbaric chamber from day 1 to day 14.  Our results revealed that HBOT has no 
effects on lesion cavity size after spinal cord hemisection even though the total number 
of macrophages/microglia was significantly reduced. We further classified the local 
macrophages/microglia into 3 different subtypes (resting, primed/activated and 
phagocytic) based on their sizes and morphologies, as indicative of their activation 
stages. Fewer activated and primed subtypes were detected in treated animals, which 
suggests that HBOT suppressed the macrophage activation.  
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The objective of our second study was to investigated the effect of acute 
treatment of VEGF+PDGF, delivered by a hydrogel based polymer, on lateral 
hemisection model at 1 and 3 month. It was demonstrated that approximately 48 hours of 
acute VEGF+PDGF delivery reduced secondary degeneration, gliosis and also promoted 
axon sprouting into the lesion cavity after injury. However, no functional improvement 
was observed. Surprisingly, no significant increase in blood vessel density was found 
after VEGF+PDGF delivery. This suggests the reduction of lesion size was not due to 
promotion of angiogenesis by VEGF+PDGF although they significantly modified the 
inflammatory response. This was evident by a shift in the population distribution and 
density of macrophages/microglia.  
We further investigated the dose dependent effect of VEGF+PDGF on SCI by 
using a mini-osmotic pump. The pump was implanted right after the injury and a week  
long delivery of high dose VEGF+PDGF (15 µg) significantly reduced the lesion size 
when compared to low dose VEGF+PDGF (5 µg) and control groups. Similar to 
previous findings, both VEGF and PDGF altered the macrophage/microglia response, 
although a significant rise in the population of ‘phagocytic’ classification or anti-
inflammatory macrophages in high dose group was observed. No neuroprotective effect 
was detected when VEGF or PDGF were delivered singly suggesting neuro-regeneration 
required the combined effects of both growth factors.  
Finally, the effect of VEGF+PDGF was evaluated in a more clinically relevant 
SCI model known as spinal cord contusion. Consistent with previous studies, the acute 
delivery of VEGF+PDGF for 7 days reduced the lesion size and increased the population 
of anti-inflammatory macrophages. In addition, promoted functional recovery was 
observed in growth factors treatment group. 
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In summary, this study demonstrated that acute delivery of VEGF+PDGF 
prevents secondary degeneration by altering the inflammatory environment of the 
injured spinal cord. To our knowledge, this is the first report demonstrated the beneficial 
role of VEGF+PDGF in SCI. 
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1Chapter 1 Introduction 
1.1 INTRODUCTION 
 
 
Traumatic spinal cord injury (SCI) causes severe and long-lasting neurological 
dysfunction as well as morbidity in humans. To date, no therapy has been shown to be able 
to treat the damaged spinal cord and the associated motor and sensory deficits together with 
severe chronic pain (O'Connor, 2006). The limited capacity for spinal cord repair after 
injury is mainly attributed to the disrupted capillary network within highly vascularised 
spinal cord, which propagates a cyclic breakdown of the blood-spinal cord barrier (BSB) 
resulting in a persistent inflammatory response and secondary degeneration (Popovich et 
al., 1996, Yancopoulos et al., 2000). 
 
A range of anti-inflammatory treatments have been trialed in an effort to limit the 
damaging effects of the dysregulated inflammatory response seen after spinal cord injury. 
This includes Methylprednisolone, which has been shown to suppress lymphocyte 
activation, macrophage infiltration and pro-inflammatory cytokine release (Benzel et al., 
1990, Oudega et al., 1999, Qian et al., 2000, Zhang et al., 1995) and Minocycline, an 
inhibitor of microglial activation and proliferation (Tikka et al., 2001) . Whilst in animal 
models these anti-inflammatory approaches have resulted in some functional improvements 
they do not necessarily correlate with dramatic reductions in lesion volume or axonal 
growth across the defect (Qian et al., 2000, Teng et al., 2004). This suggests that anti-
inflammatory approach may not be enough to prevent secondary degeneration and the 
functional improvements observed might have resulted from increased plasticity.  
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Increased angiogenesis is one of the crucial steps in endogenous repair mechanisms 
(Ferrara, 2000). However, in spinal cord, there is a dramatic loss of intact blood vessels in 
the developing cavity at 2 weeks post-injury (Hausmamn et al., 2011) and the expression of 
Vascular Endothelial Growth Factor (VEGF), a potent stimulator of angiogenesis 
(Storkebaum et al., 2004), has found to be reduced after SCI (Herrera et al., 2009) . 
Consequently, VEGF therapy has been investigated for treating SCI. Acute delivery of 
recombinant VEGF or cells over-expression of VEGF resulted in reducing tissue loss and 
ischemic cell death and improving behavioral outcomes (Kim et al., 2009, Widenfalk et al., 
2003). However, in the these studies, VEGF did not increase angiogenesis at the epicenter 
of the injury, possibly due to the lack of mature vessel formation (Casella et al., 2002, 
Yancopoulos et al., 2000). In fact, the formation of mature vasculature requires not only 
VEGF but other angiogenic factors; one of these is Platelet-derived growth factor (PDGF). 
PDGF stimulates smooth muscle cell migration which promotes blood vessel stability and 
maturation via PDGF/PDGF receptor signaling (Kohno et al., 2013, Lewis, 2007, Liu et al., 
2006). Dual delivery of VEGF and PDGF has been demonstrated to promote a robust 
angiogenic response in other tissue models (Chen et al., 2007, Hao, 2007). In addition, both 
growth factors possess neuroprotective effects (Allamargot et al., 2001, Jean et al., 2002, 
Storkebaum et al., 2004, Sun et al., 2003). This led us to consider dual growth factor 
delivery to promote angiogenesis after SCI in an attempt to reduce secondary degeneration. 
However, several issues needed to be addressed before applying both growth factors in SCI. 
First of all, SCI elicits a complex spatio-temporal response in the injured tissue, such that a 
particular growth factor treatment may only be beneficial when the growth factors are 
delivered in certain doses and delivery periods. Over-stimulation of angiogenesis and 
inappropriate delivery period may exacerbate gliosis and inflammation. Indeed, injection of 
a high dose of recombinant VEGF (20 µg) did not lead to significant improvement 
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(Widenfalk et al., 2003) whilst delayed delivery of VEGF (72 hr after injury) can also 
exacerbate the injury by increasing microvascular permeability (Benton and Whittemore, 
2003). Therefore, the delivery periods and dose of growth factors are crucial in determining 
the efficacy of the treatment. Secondly, both growth factors have been demonstrated to have 
immunomodulatory roles in the pro-inflammatory microenvironment and both growth 
factors were shown to activate monocyte recruitment and macrophages activation (Croll et 
al., 2004, Heil et al., 2000, Jendraschak et al., 1998, Krettek et al., 2001, Liu et al., 2006, 
Pierce et al., 1991). When both VEGF and PDGF were delivered adenovirally to ischemic 
muscle, there was a prolonged increase in vascular perfusion, an effect mediated via 
recruitment of inflammatory cells particularly monocytes / macrophages rather than directly 
via angiogenesis (Korpisalo, 2008).  As such, delivery of both growth factors may alter the 
inflammatory response and analysis of inflammatory cell population should be included 
after the treatment. 
In this study, different doses and delivery profile of VEGF+PDGF will be delivered 
into SCI rat models via two delivery methods; acute delivery using a polymer gel and 
prolonged delivery using an osmotic mini-pump in an attempt to reduce secondary 
degeneration after the initial traumatic damage to the spinal cord. Our hypothesis was that 
the co-delivery of VEGF and PDGF would improve intra-lesion angiogenesis and stabilize 
the BSB. We predicted that improving intra-lesion angiogenesis would reduce tissue 
hypoxia, restore the blood brain barrier, slow down the infiltration of inflammatory cells 
and provide an environment where neurogenic therapies could be readily applied 
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1.2 SPECIFIC AIMS OF THE STUDY 
 
Four specific aims have been addressed in this study. 
 
1. The first aim was to examine the effect of hyperbaric oxygen treatment (HBOT) in a 
hemisection model of SCI. The acute inflammatory response after HBOT has not 
been studied before and this was assessed by immunofluorescence 2 weeks after 
injury. We also characterised and identified the different phenotypes of 
macrophages and microglia after SCI by their morphology and size. The 
development of the analysis of inflammatory cell population was useful in studying 
the responses of macrophages / microglia in later experiments. Also, this study 
allowed us to learn how to establish the hemisection injury model as well as post-
injury care. 
 
2. The second aim was to examine the effect of VEGF+PDGF, delivered by a 
hydrogel-based polymer, on a lateral hemisection model of SCI at 1 and 3 month 
post-injury. The patch was applied immediately after injury. The progression of 
secondary degeneration was assessed by immunofluorescence with antibodies 
targeting neurons and astrocytes. The activity of macrophages/microglia was 
examined in term of their densities and morphology around the edge of lesion. 
 
3. The third aim was to investigate the effect of different delivery profiles of 
VEGF+PDGF on a lateral hemisection model at 1 month after the injury. Osmotic 
pumps loaded with 2 different doses of VEGF+PDGF (0.9 µg hr-1 and 0.3 µg hr-1 
per growth factor) were delivered acutely to the injury site via catheter for 7 days. 
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The inflammatory response and damaged tissues were assessed by 
immunofluorescence. 
 
4. The fourth aim of my study was to examine the effect of acute delivery of 
VEGF+PDGF into spinal cord contusion model. The contusion model is an animal 
model of SCI more representative of human pathology than the hemisection model. 
The injury was created by PSI infinite horizon impactor. Spinal cords were analysed 
by immunofluorescence histology. Behavioural analysis was also performed to 
assess functional recovery. 
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2Chapter 2: Literature review 
2.1 OVERVIEW OF SPINAL CORD INJURY  
 
Traumatic spinal cord injury (SCI) is a debilitating injury resulting from interruption 
of nerve connections between the brain and the rest of the body. Disruption of the nerve 
connections results in paralysis and loss of sensation below the level of the injury (Novikov 
et al., 2002a). There is an estimated 2.5 million people living with SCI, with 130,000 new 
cases reported each year around the world. The most common aetiology is car accident (43-
50%) followed by falls (18.8-37%) and violence (17%) (International Campaign for Cures 
of Spinal Cord Injury Paralysis, 2004). In Australia, there are approximately 250 people 
who are paralysed from spinal cord injury every year with over half of the patients being 
under 35 year of age (Cripps, 2006, O'Connor, 2006). An injury is defined as complete if 
motor and sensory function absent below the level of injury (van Middendorp et al., 2009). 
For incomplete injury, at least some motor and sensory function below the level of the 
injury is preserved. Patients suffering from incomplete injury may have more sensory and 
motor function on one side of the body than other (Spiess et al., 2009). 
 Currently, the treatment options for SCI are limited and there is no complete 
restorative therapy. Although the life expectancy for SCI patients continues to increase, it is 
still below the average of a person without SCI and the mortality rate remains high 
especially for severely injured persons (Strauss et al., 2006). Most patients with significant 
cord damage have permanent symptoms including motor and sensory deficits, chronic 
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severe pain, bladder, bowel and sexual dysfunction, as well as autonomic dysreflexia 
1(Freund et al., 2007). As a result, the cost of treatment and rehabilitation on SCI patients 
represents a significant burden on the patient, the health system and the community. 
Therefore, a treatment for functional improvement after SCI and associated complications is 
urgently needed. To develop effective therapeutic interventions, it is important to 
understand the pathological mechanisms involved after SCI.  
The progression of SCI is classified into 2 phases. Initially, the acute neurological 
impairment is restricted to the injury site, however this initiates a cascade of events which 
causes secondary degeneration of local tissue and a permanent neurological deficit. This is 
termed the secondary phase of the injury (Schmidt and Leach, 2003). 
 
2.2.1 Acute/Primary Phase 
The primary injury to the spinal cord occurs through the initial impact and/or persisting 
compression from the dislocated intact vertebra or from fragments of a fractured vertebral 
body (Figure 1) (Tator, 1995). The impact forces include compression, contusion, shear, 
laceration, and distraction (Scheff et al., 2003). These mechanical forces primarily damages 
the central grey matter, due to its softer and highly vascularised nature, causing a massive 
death of cells including local neurons, astrocytes, oligodendrocytes and endothelial cells in 
the vicinity of the injury site (Dumont et al., 2001b, Lu et al., 2000, Mautes et al., 2000b). 
The death of endothelial cells of local blood vessels results in haemorrhage, ischemia and 
                                                 
 
1 Autonomic dysreflexia is a syndrome characterised by sudden onset of high blood pressure caused by 
uncontrolled sympathetic nervous system in spinal cord injury patient, usually resulting from sensory 
stimulation below the level of injury.  
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oedema, disturbing the oxygen and nutrient supply to the site of injury and its surroundings 
(Jones et al., 2003). Shearing of myelinated axons causes the damage of the myelin 
membrane adjacent to axon, resulting in the accumulation of the myelin inhibitors including 
NogoA, myelin associated glycoprotein and oligodendrocyte-myelin glycoprotein at the 
injury site (Pot et al., 2002, Su et al., 2007). These inhibitors inhibit axon outgrowth and 
they are one of the significant factors responsible for the lack of regeneration in vivo at the 
later phase of the injury (Fitch and Silver, 2007, Freund et al., 2007, Pot et al., 2002, Wang 
et al., 2006).  
 
 
Figure 2-1. Traumatic impact to the spinal cord causes compression due to dislocation of intact vertebra 
or from fragments of fractured vertebrae 
(Adapted from http://www.nlm.nih.gov/medlineplus/ency/imagepages/19619.htm) 
 
In addition, the hypoxic condition induces a massive release of glutamate into the 
extracellular space from necrotic and lysed axons, neurons, astrocytes and oligodendrocytes 
(Bernards and Akers, 2006, Choi, 1994, Lustig et al., 1992, Park et al., 2004). Since 
glutamate has excitatory effects, excessive accumulation of glutamate results in over-
stimulation of ionotrophic and metabotrophic glutamate receptors which consequently 
contributes to neuronal death (Nguyen and McQuillen, 2010, Uberti et al., 2002). This 
event is known as excitotoxicity. In SCI, the extracellular glutamate concentrations increase 
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to neurotoxic levels within the first three hours after the injury (Liu et al., 1999, Liu and 
Bilkey, 1999, McAdoo et al., 1999).  
Spinal cord injury results in immediate disruption of a specialised structure called 
blood-spinal cord barrier (BSB) (Maikos and Shreiber, 2007). The BSB is a monolayer of 
endothelial cells which joined together to form tight cellular junctions by transmembrance 
proteins including occludins and claudins (Banks, 1999, Banks, 2009).  These junctions 
form a physical barrier that tightly regulates the passages of molecules between central 
nervous system (CNS) and the blood . More importantly, the presence of BSB limits the 
entry of immune cells and immune mediators into the CNS (Muldoon et al., 2013). As such, 
CNS has an distinct immune system with the rest of the body and only resident 
macrophage, known as microglia, is found CNS. Therefore, the breakdown of BSB results 
in the sudden influx of immune cells from the blood stream, dramatically alters the 
regulation of the inflammatory response in the injured spinal cord which is 
immunologically quiescent (Trivedi et al., 2006).  This dysregulation of the inflammatory 
response plays a major role in enlargement of tissue damage in the secondary phase of the 
injury.  
The breakdown of the BSB also leads to the leakage of plasma fluid into the 
extracellular space and deposition of fibrinogen, a blood clotting protein, in the spinal cord. 
This protein has been shown to activate the epidermal growth factor receptor (EGFR) 
thereby inhibiting neurite outgrowth and axon regeneration (Schachtrup et al., 2007). In 
addition to plasma proteins, there is also a massive invasion of blood circulating 
inflammatory cells into the spinal cord through the disrupted BSB (It will be discussed in 
the next section). As such, it is thought that the initial damage to the local blood vessels and 
BSB is decisive for the disruption events that cause the secondary phase of injury (Mautes 
et al., 2000a, Mautes et al., 2000b). 
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2.2.2 Secondary phase 
Many nerve fibres remain intact immediately after SCI but degenerate over the next 
few weeks or months or even years (Fig 2-2). Several combined mechanisms contribute to 
this pattern of tissue destruction including prolonged inflammatory events with invasion 
and activation of immune cells, glial scar formation, formation of free radical, continued 
disruption of BSB, and demyelination. 
 
2.2.2.1 Infiltration and activation of inflammatory cells 
 
 The breakdown of BSB unleashes the body’s natural inflammatory response to the 
injury. Infiltration of inflammatory cells, first neutrophils (within 6 h after injury) and later 
T-lymphocytes and macrophages (delayed for several days), invade the lesion site and 
surrounding parenchyma to sterilise the damaged tissue and phagocytise infectious agents 
as well as cellular debris (Crocker et al., 2006, Marracci et al., 2002, Popovich et al., 1997). 
However, neutrophils have been proposed to play a vital role in tissue destruction and 
enlargement of the lesion in the secondary injury by releasing neutrophil proteases, such as 
elastase and matrix metalloproteinases (MMP), and reactive oxygen species (Daley et al., 
2009, Jones et al., 2005b, Popovich et al., 1997). Additionally, neutrophils recruit other 
inflammatory cells and damage the vascular endothelial cells further extending the 
inflammatory response (Taoka et al., 2000, Taoka et al., 2001, Tjoa et al., 2003).  
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Figure 2-2. Representative histological sections of human spinal cord at 1 hour and 60 days after spinal 
cord injury.  At the acute phase of the injury (i.e 1 hour post injury), local cell death is observed in the central 
core area. Cell death continues and spreads radially in all directions over the weeks and months. By 60 days 
post-injury, there is a large amount of tissue loss in grey matter with only a thin rim of white matter 
remaining. This continuing tissue loss is termed secondary degeneration. (Adapted from Hulsebosch, C. 2002)     
  
2.2.2.1.1 Activation of resident microglia 
 
As mentioned before, microglia are the resident macrophages of the CNS and they are 
constitute about 13% of the total glial cell population (Watanabe et al., 1999). They are 
distributed diffusely throughout the brain and spinal cord. Microglia protect the CNS from 
invading micro-organisms and tissue damage by phagocytosis (Andjelkovic et al., 1998, 
Gehrmann et al., 1995). They also act as antigen-presenting cells to T cells. Since microglia 
are the only immune cells in the CNS, they are extremely sensitive to small pathological 
changes. Upon SCI, the resident microglia rapidly become activated as evidenced by 
hypertrophic cell bodies and retraction of processes, as early as 4 hours post injury 
(Donnelly and Popovich, 2008, Trivedi et al., 2006). The activation peak of microglia is 1 
week after injury and plateaus between 2-5 weeks (Streit, 2001, Watanabe et al., 1999). 
Activated microglia release cytotoxic substances including pro-inflammatory cytokines, 
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such as IL-1β, IL-6 and TNF-α (Flaris et al., 1993, Stammers et al., 2012). However, at the 
same time, activated microglia participate in the engulfment of myelin debris and secretion 
of neurotrophic factors including glial cell line-derived neurotrophic factor (GDNF) that 
helps to promote neuron survival (Hashimoto et al., 2005).  
 
2.2.2.1.2 Infiltration of circulating monocytes 
 
Circulating monocytes infiltrate into the lesion 2 days after injury and their activation 
peaks at the second week after the acute injury (Kigerl et al., 2006, Popovich et al., 1997). 
The infiltrated monocytes differentiate into activated macrophages in response to cytokines, 
chemokines and extracellular metabolites as well as the anoxic environment (Albina et al., 
1995, Crocker et al., 2006). In the early 1980s, despite its role in removal of cellular debris, 
the activated macrophages were viewed as detrimental by releasing pro-inflammatory 
cytokines and other neurotoxins including reactive oxygen species and nitric oxide (David 
and Ousman, 2002, Munck Petersen et al., 1990). However, recent studies have 
demonstrated the varied and complex nature of the circulating monocytes (Amano et al., 
2005, Capoccia et al., 2008, Cochain et al., 2010, Varga et al., 2008). Indeed, two main 
subsets of circulating monocytes have been identified according to their functional 
differences and they are referred as inflammatory and resident monocytes. Inflammatory 
monocytes were shown to infiltrate the spinal cord at 12 hours and 4 days after the injury 
and give rise to dendritic cells which present the antigen to the T cells and promote the 
clearance of cellular and myelin debris (Mabon et al., 2000, Naik et al., 2006, Naik et al., 
2007). Although dendritic cells were detected in injured rat spinal cord, the fate, number 
and functional role of inflammatory monocytes in SCI remain unknown (Sroga et al., 
2003). 
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”Resident” monocytes were found in the spinal cord at 2 hours and 4 days after spinal 
cord injury by using flow cytometry (Pineau et al., 2010). “Resident” monocytes are 
normally present in the blood vessels; they respond immediately to interferon-γ and 
lipopolysaccharide in the injured tissue; and they secrete pro-inflammatory cytokines and 
reactive oxygen species (Pruss et al., 2011). In other tissues, the resident monocytes stop 
producing pro-inflammatory cytokines about 8 hours after the injury and transform into 
alternative activated macrophages (M2) in the presence of IL-4 or IL-13, and glucocorticoid 
hormones (Mantovani et al., 2007). M2 cells are known to express TNF-αhigh, IL-10low, IL-
12high as well as high levels of scavenger and mannose receptor (David and Kroner, 2011). 
M2 cells play an important role in resolving inflammation and initiating tissue repair and 
angiogenesis (Nahrendorf et al., 2007). However, in the injured spinal cord, the fate of the 
resident monocytes remains unclear due to lack of characteristic markers for screening and 
identification. Recent studies have suggested that in the injured spinal cord, the 
inflammatory phase is prolonged and fails to transit to the resolution phase (Pruss et al., 
2011). Also, at 1 month after injury, inflammatory macrophages were shown to be the 
dominant subtypes in mice SCI (Kigerl et al., 2009). This suggests that microenvironment 
after SCI is pro-inflammatory and the extended presence of pro-inflammatory cytokines 
such as TNF-α and interferon results in the death of oligodendrocytes and neurons, not only 
at the site of injury but also distant from the trauma site, via caspase dependent pathways 
and mitochondrial injury/swelling (Davies et al., 2006, Fraidakis et al., 2007, Rice et al., 
2007). The failure of the transformation from “pro-inflammatory” to “anti-inflammatory” 
might be attributed to (1) failure of resident monocytes to transform to M2 macrophage or 
(2) insufficient infiltration of resident monocytes into the injured cord.  
Although this paradigm of macrophage polarization seems to be well-characterised, it 
should be noted that all these results were based on in vitro experiments which cannot 
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reflect the complexity of macrophage polarization in vivo. There is mounting evidence that 
the macrophages phenotypes are more diverse in vivo and the phenotypes maybe 
interchangeable (Daley et al., Mantovani et al., 2004, Pelegrin and Surprenant, 2009). It 
would be too simplistic to classify the functional polarization of macrophages into two 
subtypes only (Mantovani et al., 2013). 
 
2.2.2.1.3. Infiltration of lymphocytes 
 
The infiltration of lymphocytes peaks at day 7 post-injury and is in parallel with the 
activation of microglia and influx of peripheral macrophages (Donnelly and Popovich, 
2008). The number of T cells present in the injured cord remains low as compared to other 
immune cells recruited (Schnell et al., 1999). Nonetheless, T cells play an important role in 
immune defence and protection. T-lymphocytes recognise the major histocompatibility 
complex (normally myelin debris) from antigen presenting cells, including macrophages 
and dendritic cells, and become activated. Activated T-lymphocytes increase in number and 
produce cytokines and antibodies (via B-cells), which amplify the inflammatory response 
and promote injured cell removal by macrophages (Jones et al., 2005b). To date, the 
importance of T-lymphocytes after SCI remains elusive. Some studies have shown 
histological and functional improvement after SCI when immunised with myelin basic 
protein or reactive T-lymphocytes after SCI (Sicotte et al., 2003, Yoles et al., 2001) while 
others have shown impaired neurological improvement (Jones et al., 2004, Jones et al., 
2005a). 
Whether or not the inflammation is beneficial or detrimental in CNS injury has long 
been debated. In most tissues, inflammation is a self-resolving process transitioning from a 
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pro-inflammatory phase, which removes foreign bodies and/or damaged tissues, to an anti-
inflammatory phase, which dampens immune responses and promotes healing (Yang et al., 
2004). In CNS, due to its “immune-privileged” property and continued disruption of BSB 
and blood brain barrier, this transition is dysregulated resulting in prolonged inflammation 
and impaired tissue healing (Kigerl et al., 2009). 
 
2.2.2.2 Glial scar formation  
 
Astrocytes, one of the most abundant glia, are essential for normal neuronal activities. 
They provide nutrients to neurons; they are responsible for homeostatic maintenance of the 
ionic environment; and they provide biomechanical support for BSB etc (Sofroniew, 2000, 
Sofroniew, 2005). In response to SCI, astrocytes become reactive (characterised by cellular 
hypertrophy) and proliferate (astrogliosis) in the prolonged inflammatory microenvironment 
near the lesion resulting in the formation of a glial scar (Brambilla et al., 2005). This scar is 
a dense network composed of astrocytes, microglia and macrophages, and menigeal 
fibroblasts combined with neuro-inhibitory molecules such as chondroitin sulfate 
proteoglycans (CSPGs) (Sharma et al., 2012). This creates a molecular and physical barrier 
for nerve regeneration (Figure 2-3) (Fitch and Silver, 2007, Sofroniew and Vinters, 2010). 
CSPGs are a diverse group of molecules consisting of a core protein attached to specific 
types of glycosaminoglycan side chains (Iseki et al., 2012). After SCI, the expression of 
CSPGs, including aggrecan and neurocan, is significantly increased in reactive astrocytes in 
the glial scar tissue (Kwok et al., 2008).  
The role of astrogliosis and the glial scar remains puzzling but this process is conserved 
in vertebrate evolution, suggesting a beneficial or protective function (Sofroniew, 2005). 
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One of the beneficial roles of glial scar may be restricting inflammation at the lesion area 
and therefore, limiting the progression of secondary degeneration (Rolls et al., 2008).  
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Figure 2-3 . Reactive astrogliosis and glial scar formation after spinal cord injury (SCI).Reactive 
astrogliosis and glial scar formation after spinal cord injury (SCI). In response to SCI, astrocytes become 
activated (as indicated by the hypertrophic cell bodies) and proliferated to form a dense network comprise of 
astroglial processes, microglia and macrophages, menigeal fibroblast known as glial scar (Bottom panel). The 
glial scar is thought to be the major physical and biochemical barrier for neurogenesis after SCI. No glial 
scaring is detected at the area distant to lesion (Top panel).                                          
(Adapted from Sofroniew and Vinters, 2010) 
 
2.2.2.3 Demyelination and associated neuro-inhibitors 
 
Healthy CNS axons are wrapped in a myelin sheath, which increases the speed of nerve 
impulse transmission. The myelin sheath is composed of 75-80% of lipid and 20-25% of 
protein by weight (Murin et al., 2009) and it is produced by oligodendrocytes. After SCI, 
macrophages and microglia fail to remove the myelin debris which lead to oligodendrocytes 
apoptosis and chronic demyelination (Hausmann, 2003). The demyelinated axons are then 
separated from the neuron’s nucleus and degenerate over time, a process known as Wallerian 
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degeneration or anterograde degeneration (Irvine et al., 2004, Perrin et al., 2005). The failure of 
clearance of apoptotic oligodendrocytes and myelin debris by macrophages causes the 
accumulation of nerve-inhibitory myelin associated molecules. These myelin associated 
inhibitors, including myelin-associated glycoprotein, oligodendrocyte-myelin glycoprotein, and 
Nogo-A, have been shown to inhibit neurite outgrowth in vitro (Crocker et al., 2006, 
Domeniconi et al., 2002, Karnezis et al., 2004, Tang et al., 1997, Wang et al., 2002a, Wang et 
al., 2002b, Woolf and Bloechlinger, 2002). Elongation of axons was observed in myelin-free 
spinal cords and immunisation of mice with antibodies against myelin inhibitors prior to CNS 
injury has shown axonal regeneration as well as partial behavioural improvement (Hauben et 
2001, Yu et al., 2007). All these studies suggest that the myelin inhibitors, released from the 
injured white matter, contributed to the early neuro-inhibitory microenvironment before the 
glial scar formed.  
 
2.2.2.4  Formation of free radicals and other neurotoxic molecules 
 
Free radicals such as superoxide and hydroxyl play an important role in normal cell 
metabolism and they are also produced as a by-product in the immune response such as 
neutrophil signalling. Since free radicals are extremely reactive, in healthy spinal cord, there are 
number of enzymes such as superoxide dismutase and catalase which help to reduce the number 
of free radicals to a sustainable or balanced concentration (Grabitz et al., 1990, Honegger et al., 
1989). After SCI, the hypoxic-reperfusion injury, together with the neutrophil signalling and 
excitotoxicity (mentioned below), induce the production of large amount of free radicals which 
enzymes cannot clear away (Basu et al., 2001, Nishibe et al., 1989). These free radicals cause 
membrane lipid peroxidation and the formation of aldehyde products, which disturb the 
function of several key metabolic enzymes or proteins including Na+/K+-ATPase (Ditor et al., 
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2004, Li et al., 2001) and glucose transporter (Nagamatsu et al., 1993). A consequence of this is 
the loss of energy metabolism in mitochondria and initiation of programmed cell death in neural 
cells (Lewen et al., 2000). Since CNS is rich source of polyunsaturated fatty acids, the damage 
of free radicals is still detrimental even though they have a short half-life. 
 
Elevation of excitatory amino acid level especially glutamate in extracellular space was 
observed in many experimental SCI animal models (Stewart et al., 1991, Wells et al., 1994, 
Zhan et al., 1989). Glutamate is a major excitatory neurotransmitter in mammalian CNS and it 
is normally cleared from the synaptic cleft mainly by astrocytes (Rothstein et al., 1996). In SCI, 
glutamate clearance is impaired causing the extracellular glutamate in white matter to reach 
neurotoxic level. The prolonged excitatory activation of ionotropic N-methyl-D-aspartate 
(NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors as well 
as metabotropic glutamate receptor lead to neuronal cell death (Caccamo et al., 2004, Park et 
al., 2004). This process is known as excitotoxicity. However, it is commonly accepted that 
ionotropic glutamate receptors are responsible for the harmful effect of excitotoxicity. The 
continued binding of excess glutamate to NMDA receptor induces the uncontrolled influx of 
calcium ions (Ca2+). This massive overload of intracellular Ca2+ leads to activation of calpain 
and mitochondrial oxidative phosphorylation which ultimately causes apoptosis (Caccamo et 
al., 2004, Choi, 1992, Lawson and Lowrie, 1998). The AMPA receptor is involved in 
regulating the influx of sodium ions (Na+). The continued activation of AMPA receptors, due to 
the unwarranted glutamate level, induces influx of Na+ which consequently leads to osmotic 
imbalance and swelling of the neurons (Caccamo et al., 2004). The excess swelling of neurons 
can leads to necrosis (Park et al., 2004). 
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To conclude, the underlying mechanisms of secondary injury are multi-factorial and 
complex. However, these mechanisms are mainly or partly driven by the prolonged 
inflammatory event suggesting that resolving inflammation might be the primary target for 
stopping the secondary degeneration or even enhancing nerve-regrowth.  
 
2.2.3 Regenerative processes after traumatic spinal cord injury  
 
Although spinal cord axons fail to regenerate after injury, a vigorous natural repair response 
is initiated. Expression of neurotrophic factors such as fibroblast growth factor-2, IL-6, 
nerve growth factor (NGF), glial-derived neurotrophic factor (GDNF), and VEGF are 
increased (Cafferty et al., 2004, King et al., 2004, Lagord et al., 2002, Madiai et al., 2003, 
Romero et al., 2001, Skold et al., 2000). These factors serve to increase neuron and 
oligodendrocyte survival, induce axonal sprouting, and promote blood vessel formation as 
well as restoring the BSB. However, increased expression of these factors is either not 
sufficient to overcome the inhibitory mechanisms or not long enough to promote long 
projecting axon regeneration across the injury site, thereby leading to the lack of substantial 
functional recovery (Hagg and Oudega, 2006). In humans, the repair processes are aborted 
by the end of the 3rd week and the degenerative processes take over causing a wound gap 
that leads to permanent paralysis below the level of injury (Kalderon, 2005).  
 
2.2.4 Beneficial role of inflammation 
 
Although a prolonged inflammatory response contributes to the secondary degeneration 
after SCI, it plays a role in neuro-constructive events. In olfactory epithelium, one of the 
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few neurological structures that are capable of generating neurons, the survival, 
degeneration as well as replacement of neurons has been strongly correlated with the 
presence of macrophages (Borders et al., 2007).  
Proinflammatory cytokines also induce the production of neurotrophic factors which 
help to promote repair. Besides neurotrophic factors, proinflammatory cytokines and 
chemokines released from the immune cells have the ability to modulate neural progenitors 
(Das and Basu, 2008). TNF-α, which is up-regulated in most immune responses and in 
neurodegenerative diseases, was shown to promote proliferation and survival of 
hippocampus neurons by binding the TNF receptor 2 (TNFR2). Arnett el. al. also found that 
TNF-α and TNFR2 were up-regulated in demyelination and blockage of either TNF-α or 
TNFR2 delayed the remyelination process (Arnett et al., 2001, Plant et al., 2005). This 
study suggests that TNF-α promotes proliferation of oligodendrocyte progenitors and 
remyelination in CNS. In addition, in vitro treatment of neurospheres2 derived from the 
subventricular zone with TNF-α increased the proliferation of the adult neural stem cells, 
suggesting TNF-α is a positive regulator of neurogenesis (Widera et al., 2006). However, 
TNF-α was also shown to inhibit the proliferation and generation of neurons in the 
hippocampus (Iosif et al., 2006, Pannu et al., 2005). These opposite effects of TNF-α are 
mainly attributed to the distinct signalling pathways mediated through TNFR1. Binding of 
TNF-α to the TNFR1 induces apoptosis and this exacerbating effect is thought to 
responsible for the secondary dieback after SCI (Mizoguchi et al., 2008, Tracey et al., 
2008). As a result, modulating the role of TNF-α may help to protect the progressive 
secondary cell death after SCI. Besides TNF-α, stromal cell-derived factor-1 (SDF-1), 
                                                 
 
2 Neurosphere formation is the surrogate assay of neural stem cells or neural progenitor cells in vitro 
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which is a chemoattractant for lymphocytes, is shown to promote survival and proliferation 
of neurosphere cells (Ni et al., 2004, Tran et al., 2007). Nonetheless, the anti-proliferative 
or/and anti-survival role of other pro-inflammatory cytokines such as IL-6, IL-18 and 
interferon-γ suggest that the role of inflammation is very complex (Ben-Hur et al., 2003, 
Chiang et al., 2006, Kurt et al., 2008, Liu et al., 2005, Okada et al., 2004). Whether the 
inflammatory response has a beneficial or detrimental effect following SCI probably 
depends on different factors, including the timing, magnitude, cytokines, immune cells 
involved and duration of inflammation. 
 
2.3 Current Therapeutic approach 
Although our understanding of SCI has improved tremendously over the last 
decades, there is still no significant improvement in treatment options to offer patients 
(Hagg and Oudega, 2006). Current treatment involves decompression surgery to remove the 
bones that compress the spinal cord as well as to stabilize the spine. The only FDA 
approved drug for SCI is methylprednisolone (MP), which is synthetic steroid used to 
reduce the size of haemorrhage, suppress immune response and inhibit the formation of free 
radical-induced lipid peroxidation (Hall, 2001, Mu et al., 2000, Taoka et al., 2001). 
However, the effectiveness of MP is now considered not to be significant (Hall, 2001, 
Melo-Filho et al., 2009) and the use of MP increases the risk of complications including 
pneumonia or other infections after surgical stabilization (Molano Mdel et al., 2002). As a 
result, many centres do not use this drug. Another treatment for SCI is physical 
rehabilitation such as weight-supported ambulation training (Protas et al., 2001). It is 
thought that the gait training might re-activate the rhythmic neural activity produced by 
central pattern generator in spinal cord (Gardner et al., 1998). However, whilst this is 
 Page 23 
Yun Wai Young 2010 Page 23 
currently the best available treatment, the effect of this treatment is very modest and should 
be considered as a secondary treatment for SCI. 
 
2.4 Current research toward SCI 
Because there is a lack of effective treatment for restoring the neurological function 
and associated complications, novel treatments are urgently needed. Over the last few 
decades, several approaches have been successfully established in animal models. To 
summarise, there are five different strategies in spinal cord regeneration; 
1.   Providing extra cell types such as stem cells to bridge the spinal cord lesion 
2.   Eliminating the non-permissive environment for neuron regrowth 
3.   Promoting the regeneration of interrupted nerve fibre tract by nerve growth stimulating 
factors  
4.   Enhancing central nervous system (CNS) plasticity by promoting compensatory growth 
of uninjured/intact nerve fibres 
5.   Stoping or reducing the inflammation associated with SCI 
 
 
2.4.1 Cellular replacement 
 Stem cells hold great promise as a source for replacing neurons or glia in the CNS. 
They are multipotent3 (pluripotent4 for embryonic stem cell) and can be propagated into 
                                                 
 
3 Able to give rise to several cell types belonging to the specific organ or system. For example, neural stem 
cells can only give rise to three lineages in the nervous system 
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large numbers in vitro (Murrell et al., 2005, Okano, 2002). Therefore, embryonic and neural 
stem cells have been transplanted into SCI animal models and some degree of functional 
improvement in hindlimb function has been reported (Groebner et al., 2006, Okano et al., 
2005). One of the typical examples is a study carried out by McDonald et al. who 
transplanted mouse embryonic stem cells into the injured rat spinal cord (McDonald, 1999, 
McDonald et al., 1999). The animals showed modest functional improvement, assessed by 
BBB locomotion score, but the histology analysis suggested that most of the grafted cells 
differentiated into oligodendrocytes (43%) and astrocytes (19%) rather than neurons (8%). 
Other studies carried out by Nakamura et al., Pallini et al. and Liu et al. also showed similar 
findings that grafted stem cells were mainly restricted to the oligodendrocyte lineage and 
participate in the remyelination of surviving axons (Liu et al., 2000, Nakamura et al., 2005, 
Nishimura et al., 2013, Pallini et al., 2005). This can help explain why stem cell 
replacement strategies show little functional improvement because there is no restoration of 
neurons and their synaptic reconnection remains low in the injured animal,  although in one 
recent study grafted human neural stem cells predominately differentiated into a neuronal 
lineage in injured rat spinal cord (Yan et al., 2007). However, in this study, the spinal cord 
lesion was mild and BSB remained intact during the operation. Furthermore, use of nude 
rats might have reduced the scarring after SCI and this suggests that the non-permissive 
environments such as glial scars that form after the injury direct the grafted stem cells, 
resulting in oligodendrocytes and astrocytes but not neurons.  Recently, transplantation of 
mesenchyma stem cells into rat injured spinal cord has been shown to promote macrophage 
activation which contributed to functional recovery (Nakajima et al., 2012). This highlight 
                                                                                                                                                     
 
4 Able to give rise to all cell types in the body. 
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the complexity of microenvironement after SCI and the beneficial effects reported from 
stem cell transplantation might be due to alteration of inflammation (Cusimano et al., 
Another cell type that has been extensively investigated is olfactory ensheathing cells 
(OEC) from the olfactory mucosa (an adult tissue that is regenerated and repaired 
throughout life) (Mackay-Sim and St John, 2011). OECs elicit remyelination of 
demyelinated spinal axons, promote axonal regeneration and restore synaptic reconnection 
(Barnett and Riddell, 2004, Li et al., 2003, Ramon-Cueto and Nieto-Sampedro, 1994, 
Ramon-Cueto et al., 1998).  After transplantation into intact and injured spinal cord, both 
rat and human OECs were able to survive and migrate in the spinal cord (Deng et al., 2006). 
When OECs were transplanted into complete spinal cord transection model, improved 
functional recovery as well as  growth of axons across the transection site was reported (Lu 
et al., 2002). In other studies, histological analysis of OECs-transplanted animals showed 
reduced lesion cavity and lower expression of CSPG and glial fibrillary acidic protein 
(intermediate filament protein in glial cells) (Kalincik et al., 2010, Keyvan-Fouladi et al., 
2003, Li et al., 2011, Senior, 2002) . OEC also prevented the loss of parenchyma and 
reduced the number of reactive astrocytes at lesion site compared to the controls (Chuah et 
al., 2004). Recently, a three year Phase 1 clinical trial in testing the safety of autologous 
transplanting OECs into human paraplegia has been completed (Feron et al., 2005, Mackay-
Sim et al., 2008). In the study, there was no tumour by the induced cells and no 
development of syringomyelia in patients transplanted with OECs after 3 years. 
Interestingly, among the three OECs transplanted patient suffering complete paraplegia, one 
transplant recipient had an improvement in light touch and pin prick sensitivity. This 
suggests that OEC transplantation is safe and feasible (Wu et al., 2012).  
 In addition to OEC, Schwann cells, the supporting cells of the peripheral nervous 
system (PNS), were also heavily investigated in SCI. Similar to oligodendrocytes in CNS, 
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Schwann cells provides myelination for peripheral axons(Jessen and Mirsky, 2010). 
Schwann cells also known to be a source of neurotrophins and other growth factors that 
stimulated the axonal regeneration in vitro (Taylor and Bampton, 2004). For these reasons, 
Schwann cells are believed to be one of the possible candidates of cell transplantation 
therapy for SCI.  When these cells were transplanted into SCI animal models, reduced post-
traumatic astrogliosis and improved remyelination were observed but no regeneration of 
corticospinal tract as well as functional recovery was detected (Bondan et al., 2010, Brook 
et al., 1998, Martin et al., 1996, Oudega et al., 2001) . The limited ability of Schwann cell 
to promote recovery might be attributed to their poor survival rate and limited migration in 
the injured CNS (Fouad et al., 2005, Martin et al., 1996). Therefore, Schwann cells 
transplantation therapy is normally pursed as part of combination approaches (Guest et al., 
2005, Nagoshi et al., 2011, Sharp et al., 2010, Siriphorn et al., 2010) . 
More recently, stem cells that were pre-differentiated into neural precursors (Cao et 
al., 2002, Glazova and Krasnovskaya, 2001, Harel and Strittmatter, 2006) or genetically 
modified to overexpress neurotrophins (Sasaki et al., 2009a, Zhang et al., 2007) were 
transplanted into different SCI animal models. However, transplantation of neuronal-
restricted precursor cells into contused spinal cord only yielded a small percentage of 
neurons while the majority of transplanted cells remained undifferentiated (Cao et al., 
In the same study, the majority of the neuronal-restricted precursor cells differentiated into 
neurons when transplanted into healthy spinal cords. Therefore, it is postulated that the 
microenvironment created by unresolved inflammatory response is in favour of glial cell 
differentiation rather than neurogenic differentiation. Similarly, most of the studies 
transplanting genetically modified cells into injured spinal cords did not show they were 
able to differentiate into neurons even though some histological and behavioural 
improvements were detected, when compared to treatments with stem cells alone treatment  
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This improvement might only be attributed to the over-expression of neurotrophins and 
hence the stem cell was only effectively a “vehicle” or cellular scaffold for gene or growth 
factor delivery.  
Recently, a phase I clinical study has begun in which oligodendrocyte progenitor 
cells, derived from embryonic stem cells, are being transplanted into the injured human 
spinal cord (Geron, 2010). However, injection of these cells acutely have been associated 
with cyst formation which hinders the progress of the clinical trial (Thomas and Moon, 
2011). On the other hand, cell transplantation therapy may be quite appropriate for chronic 
injuries. However, delayed transplantations normally resulted in limited functional recovery 
(Ratcliffe et al., 2011, Thomas and Moon, 2011). In addition, the exact mechanism(s) 
whereby the procedure of cellular transplantation enhances recovery of function are not 
well understood.   Therefore, vigorous testing for safety as well as understanding the  
mechanism(s) should be carried out before applying stem cell in humans clinically. 
 
2.4.2 Eliminating the inhibitors  
 
Since glial scarring and its associated inhibitory molecules are recognised as 
important in the prevention of nerve regeneration, they have been targeted as one of the 
possible treatment options. Administration of chondroitinase ABC, which is able to digest 
chondroitin sulfate GAG side chains on the protein core of CSPG and reduce their 
inhibitory effects on neurite growth, has been injected in different SCI animal models 
(Morgenstern et al., 2002) . Intrathecal delivery of chondroitinase ABC into the rat with a 
nigrostriatal tract axotomy has been shown to promote nigrostriatal tract regeneration 
(Moon et al., 2001).  Acutely infusion of chondroitinase ABC into the site of the injury 
resulted in axonal sprouting, plasticity of uninjured pathway and functional improvement  
 Page 28 
Yun Wai Young 2010 Page 28 
after SCI (Bradbury and Carter, 2011, Carter et al., 2011, Hyatt et al., 2010, Jefferson et al., 
2011, Tom et al., 2009). However, Iseda and his colleagues have found that a single high 
dose injection of chondroitinase only reduces glycosaminoglycans and promotes 
corticospinal tract regeneration in hemisection SCI model but not contusion (Iseda et al., 
2008). Also, the retracted corticospinal tract failed to grow across the gliotic regions despite 
efficient degradation with chondroitinase in contusion model suggesting that other 
inhibitors of axonal growth persist in the gliotic zone. As a result, the role of chondroitinase 
alone on the treatment of spinal cord regeneration remains unclear and it is mainly used in 
combination with other cell transplant treatments (Chau et al., 2004, Fouad et al., 2005, 
Yick et al., 2004, Yick et al., 2000).  
Myelin-associated proteins such as Nogo-A also play an important role in limiting 
axonal regeneration and plasticity after SCI. Nogo-A contains 3 different active sites in 
which N-terminal region inhibits fibroblast spreading and the middle Nogo-A specific 
axons as well as C-terminal region (Nogo-66) induce growth cone collapsing (Oertle et al., 
2003). Delivery of anti-Nogo-A antibodies into the spinal cord hemisectioned rats (Li et al., 
2003) has been shown to promote compensatory corticospinal sprouting. In primates, anti-
Nogo-A treatment also promotes manual dexterity and corticospinal tract sprouting after 
unilateral cervical spinal cord lesion (Freund et al., 2007, Schwartz et al., 2009).However, 
anti-Nogo antibodies are only specific for Nogo but not other myelin-associated proteins 
such as myelin-associated glycoprotein and oligodendrocytes myelin associated 
glycoprotein (Wang et al., 2010). Therefore, the lesion after anti-Nogo treatment remains 
full of other neuro-inhibitory molecules suggesting that complete nerve regeneration is 
almost impossible and the beneficial gain might be a result of increased neuronal plasticity. 
In addition, the optimal time point for anti-Nogo A treatment remains undermined and 
delayed delivery (2 weeks ) of Nogo A antibody has no effect on injured spinal cord 
 Page 29 
Yun Wai Young 2010 Page 29 
(Gonzenbach et al., 2012). It is also shown that anti-Nogo A treatment inhibits angiogenesis 
in CNS injury (Walchli et al., 2013).  A Phase I clinical trial of human anti-Nogo A 
antibody has been recently completed (Zorner and Schwab, 2010). As a Phase I trial, the 
study investigated the pharmacokinetics, safety tolerance and correct dose of antibody. 
Intravenous injection of Nogo-A antibody has been shown to be tolerated in human (Pernet 
and Schwab, 2012). However, the therapeutic effect of anti-Nogo-A treatment in human 
SCI remains unknown. 
2.4.3.  Neurotrophic factors 
 
Nerve growth factor is widely believed to be one of the most important neurotrophic 
factors in the nervous system as it involved in axonal growth, neuron survival and 
differentiation, and synaptic reconnection (Burdick et al., 2006, Oudega and Hagg, 1999, 
Ramer et al., 2000). The effects of NGF in the spinal cord were first studied in a spinal cord 
hemisection model (Hulsebosch et al., 1984a). Surprisingly, treatment of NGF (daily for the 
duration of 1 month) did not promote sprouting of unmyelinated axons whereas treatment 
with anti-NGF antibodies induced approximately 7% more unmyelinated axons on the 
lesion side. Another study re-examined the role of NGF by continuous infusion of NGF 
using an osmotic mini-pump, into the injured cervical dorsal roots (Ramer et al., 2000). 
Regrowth of sensory fibres were identified by positive staining for calcitonin gene related 
peptide (CGRP) which is marker for small diameter, unmyelinated axons. However, the 
regrowth of CGRP fibers is closely related to pain and autonomic dysreflexia (Christensen 
and Hulsebosch, 1997). All these results suggested that NGF has a major role on the 
peripheral sensory nerve but not on the spinal cord (Cirillo et al., 2010, Hu et al., 2010). 
Therefore, NGF might not be a good candidate for SCI treatment.  
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Neurotrophin-3 (NT-3) is another potential therapeutic drug for treating SCI as it 
promotes the growth of corticospinal axons after injury (Grill et al., 1997, Ramer et al., 
2000, Schnell et al., 1994, Taylor et al., 2006). NT-3 also plays an important role in 
neurogenesis by enhancing the differentiation of new neurons (Grill et al., 1997). However, 
NT-3 delivery in the model of spinal cord injury only promotes corticospinal axon growth 
of host grey mater surrounding the lesion site but not penetrating the injury site (Grill et al., 
1997, Jones et al., 2000). This highlights the inhibitory microenvironment that stops the 
growth of fibres through the lesion site. Therefore, NT-3 treatment is normally applied with 
other combinatorial therapies to enhance the therapeutic effects.  For example, 
transplantation of NT-3-secreting human umbilical cord mesenchymal stromal cell (Shang 
et al., 2011) and agarose scaffold seeded with bone marrow stromal cells expressing NT-3 
(Gros et al., 2010)into SCI animal models resulted in functional and histological 
improvement and regeneration of long-tract axons through the injury site respectively. 
Brain derived neurotrophic factor (BDNF) has also been investigated in SCI models. 
Infusion of BDNF into spinal cord contusion model resulted in hindlimb stepping 
enhancement and cholinergic fiber sprouting with only slight improvement in behaviour 
and histological analysis (Jakeman et al., 1998). Further studies by other groups suggested 
that application of BDNF into SCI rat models also enhances ascending sensory axon 
regeneration and oligodendrocyte survival (Koda et al., 2004, Song et al., 2008). In 
delivery of BDNF using osmotic pump into dorsally hemisectioned rats promoted the 
connection of corticospinal neurons onto commissure propriospinal interneurons5 at 
                                                 
 
5 Propriospinal interneurons are defined as nerve cells only reside in the spinal cord with projections normally 
longer than 1 segment .  
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cervical level and some functional improvement (Vavrek et al., 2006). This suggests that re-
routing of corticospinal tract into propriospinal tract might be induced by BDNF treatment. 
However, this increased connection only occurred in cervical enlargement section but not in 
thoracic level which is more important in locomotion movement and control (Song et al., 
2008). Similar to NT-3, BDNF-overexpressing human mesenchymal stem cells have been 
transplanted in rat spinal cord transection injury model resulted in sprouting of injured 
cortocospinal tract and improved locomotion recovery(Sasaki et al., 2009b, Ying et al., 
2008).  
Interestingly, combined infusion of NT-3, NGF and BDNF did not promote greater 
regeneration than single neurotrophin infusion suggesting that the mechanism of 
regeneration is related to the inhibitory nature of the glial scar and associated inhibitors 
together with P75NGFR neurotrophin binding domain present on the macrophages and 
lymphocytes at the lesion. This suggests that spinal cord injury is multifaceted and 
treatment for SCI may involve multidisciplinary approach.  
 
2.4.4 Tissue Engineering 
Growth factors and cytokines are key regulatory proteins that modulate neuronal 
survival, axonal growth, neurotransmission, blood vessel restoration etc. However, a single 
injection of growth factors may not be enough to achieve functional recovery of SCI. As a 
result, development of a drug delivery system capable of sustained release of growth factors 
is necessary. Recent advances in scaffold and polymer technology provide an excellent 
approach for long term drug delivery. The advantage of using scaffolds to deliver drugs is 
that a wide range of scaffolds can be selected by considering their degradation rate, release 
profile, and other chemical and physical properties. Also, growth factors that are 
 Page 32 
Yun Wai Young 2010 Page 32 
encapsulated in the scaffold normally retain their bioactivity over period of time (Flynn et 
al., 2003). Some of the scaffolds also support tissue in-growth and guide nerve regeneration 
(Jain et al., 2006a, Rokhade et al., 2007, Wang et al., 2006). In addition, the rates of drug 
release and degradation can be easily modified by using variety of cross-linking schemes 
(Willerth and Sakiyama-Elbert, 2007). As a result, different scaffolds have been developed 
for different purposes such as delivery drugs or cells for spinal cord regeneration. 
Piantino et al. have developed a polyethylene glycol-Poly (lactic acid) (PLA) scaffold 
which is capable of releasing NT-3 for 14 days in vitro (Piantino et al., 2006). In vivo 
studies of these scaffolds in spinal cord hemisection model of rat, promoted axonal 
sprouting and minor functional improvement compared to untreated group. Maquet and 
coworkers have investigated the effects of spinal cord regeneration using Poly (D, L-
lactide) foams modified by poly (ethylene oxide)-block-poly (D, L-lactide) copolymers and 
FGF1 (Maquet et al., 2001). Delivery of FGF1 by this polymer construct was shown to 
promote angiogenesis, cellular migration and axonal regrowth in SCI model. Another study 
done by Winter et al. investigated the ability of PEG-PLA scaffolds for controlled release 
of NGF (Winter et al., 2007). Higher ratios of PLA to PEG result in longer NGF delivery 
time course (up to 20 days) as PLA acts a degradable linker. However, some of the proteins 
are trapped in the polymer if the ratio of PLA is too high. This scaffold has showed the 
ability to be able to deliver biologically active NGF as neurite outgrowth was observed in 
PC12 phaeochromocytoma cell line in vitro. Other neurotrophic factors including BDNF, 
ciliary neurotrophic factor glial cell-derived neurotrophic factor and FGF2 have also been 
encapsulated in different scaffolds for treating SCI and most of them showed functional 
recovery and nerve regeneration (Burdick et al., 2006, Chen et al., 2001, Grothe et al., 
2006, Ishii et al., 2006, Jain et al., 2006b).  
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Scaffolds are also used to provide biomechanical support and guidance for nerve 
regrowth. These scaffolds normally comprise of guidance channels to guide axon growth 
from the proximal nerve stump towards the distal nerve (Piotrowicz and Shoichet, 2006). 
Application of nerve guidance scaffolds has been successful in peripheral nervous system 
but not in CNS (Bellamkonda, 2006). No report has been proved that implantation of nerve 
guidance channel alone into SCI rat model promotes functional recovery even though some 
axonal regeneration in the scaffold were reported in several studies (Novikov et al., 2002b, 
Spilker et al., 2001, Tsai et al., 2004, Tsai et al., 2006). As such, guidance channels are 
normally augmented with different combination therapies including incorporation of 
Schwann cells (Mosahebi et al., 2001, Oudega et al., 2001) and/or growth factors (Bamber 
et al., 2001, Moore et al., 2006). However, one of the major problems of the nerve guidance 
channel is the formation of dense astrocytic scar at the border between spinal cord stump 
and scaffold which might inhibit the nerve growth and reconnection (Guest et al., 1997, 
Tsai et al., 2004). 
 
2.4.5 Inflammation modulating strategies 
 
2.4.5.1 Anti-inflammatory strategies 
 
Since prolonged inflammation is the major contributor for degeneration after SCI, a 
range of anti-inflammatory treatment strategies have been employed to dampen the 
detrimental effects from the dysregulated inflammatory response (Laliberte and Fehlings, 
2013). One of the classic examples of anti-inflammatory therapies is Methylprednisolone 
which has been shown to inhibit lymphocyte activation, macrophage infiltration and pro-
inflammatory cytokine release (Miljkovic et al., 2009, Momcilovic et al., 2008, Naso et al., 
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1995, Oudega et al., 1999). However, the effect of Methylprednisolone remains 
controversial (Chan, 2008, Ito et al., 2009, Liu et al., 2009, Sayer et al., 2006). Recently, a 
study carried out by Pereira et. al. (2009) suggested that the Methylprednisolone did not 
improve histological and functional outcome after spinal cord contusion injury in rats. 
Application of non-steroidal anti-inflammatory drugs such as Ibuprofen have also been 
shown to reduce tissue edema and histological damage of histological damage and enhance 
axonal remyelination and functional recovery in rodent SCI, through inactivation of RhoA 
pathway (Conrad et al., 2005, Fu et al., 2007, Gross et al., 2007, Schwab et al., 2004, Sung 
et al., 2003, Xing et al., 2011). The activation of the RhoA proteins, after SCI, induces the 
expression of axon growth-suppressive proteins and growth cone collapse in neurons (Dill 
et al., 2010).  Therefore, blocking of RhoA production using Ibuprofen has induced some 
degree of axonal regeneration (Fu et al., 2007). Recently, a siRNA targeting RhoA has been 
developed for SCI treatment (Otsuka et al., 2011). Intrathecal delivery of this siRNA into 
contused spinal cord promoted the serotonergic axonal regrowth caudal to the injury site 
and conserved white matter with lower accumulation of activated macrophages. However, 
no significant improvement in locomotion was detected in this treatment.  
Another example of anti-inflammatory treatment is Minocycline which is an inhibitor 
of microglial function and T-cell infiltration (Beattie, 2004, Nikodemova et al., 2010, Tikka 
et al., 2001, Tikka and Koistinaho, 2001). Similar to other anti-inflammatory approaches, 
the application of Minocycline in traumatic SCI animal models has resulted in modest 
functional improvement but does not necessarily correlate with dramatic reductions in 
lesion volume or axonal growth across the defect (Casha et al., 2012, Pinzon et al., 2008, 
Saganova et al., 2008, Stirling et al., 2004, Teng et al., 2004). These results suggest that an 
immune-suppressing strategy may not activate the intrinsic repair mechanisms which are 
most likely needed for maximising functional gains.  
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2.4.5.2 Promoting inflammation strategies 
 
Since the application of anti-inflammatory treatments only yield modest beneficial or 
even detrimental effects, an effort has been trailed to boost inflammatory response after SCI 
given its pivotal role in physiology and pathology in all tissues . Mounting evidence 
suggests that increased population of immune cells especially macrophages or T cells to the 
local microenvironment that was thought to be “overwhelmed” by immune cells can be 
beneficial after SCI (Guerrero et al., 2012, Popovich et al., 2001). In addition, comparison 
of the inflammatory responses of the CNS and PNS after injury has shown that the 
macrophage invasion into white matter of CNS is delayed and less intensive as compared to 
the PNS (Perry et al., 1987, Schnell et al., 1999, Sminia et al., 1987). PNS can regenerate 
after injury. It is proposed that the phagocytic activity of peripheral macrophages helps to 
promote the removal of cellular and myelin debris and hence, promoting a more favourable 
microenvironment for nerve regrowth. To test this hypothesis, Schwartz’s group 
transplanted peripheral blood-derived macrophages that were pre-incubated in PNS tissue, 
into an optic nerve injury model (Lazarov-Spiegler et al., 1999). By means of anterograde 
tracing and histological staining, some axonal regrowth was detected and correlated with 
the abundant accumulation of activated macrophages along the distal part of the transected 
axons. Modest recovery of behaviour was also detected in the same study.  However, 
further attempts to transplant activated macrophages into injured spinal cord yield both 
positive and negative results in different SCI models (Gensel et al., 2009, Kigerl et al., 
Popovich et al., 2002) and clinical trial (Lammertse et al., 2012) .  This might be attributed 
to several reasons. Firstly, macrophages and microglia change their phenotypes and 
function in response to signals in lesion environment (Rolls, 2008, (Shin et al., 2013) . They 
are also are very sensitive to the other changes in the microenvironment (Leskovar et al., 
2000). Any change in composition of  the cellular milieu and/or tissue integrity will 
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undoubtedly affect the local microenvironment, results in different activation stage and  
phenotypes of the transplanted macrophages as well as the local macrophages/microglia 
(Gensel et al., 2011). Secondly, the activated macrophages were stimulated by the products 
derived from microorganisms such as lipopolysaccharide and these strongly activated 
macrophages share no resemblance to activated macrophages/microglia in traumatised 
tissue which is normally free of microorganisms (Campagnolo et al., 2008, Rolls et al., 
2008). Therefore, the macrophage activation protocol theoretically should approximate 
better the local inflammatory microenvironment after SCI. Thirdly, transplanted 
macrophages were obtained from different sources including blood and skin and different 
macrophages might activate differently with the same activation protocol (Bonecchi et al., 
2004). Fourthly , the efficacy of the macrophage transplantation treatment was also found to 
be dependent on the timing and the site of injection (Schwartz and Yoles, 2006, Ziv et al., 
2006). Therefore, in order to develop an optimised macrophage treatment, several issues 
have to be addressed: what is the fate and degree of recruitment blood-derived 
What is the exact role of activated resident microglia SCI? What is the difference between 
infiltrated macrophages and resident microglia? How are the signals in the 
microenvironment affect the phenotype and function of macrophages/microglia? Are their 
phenotypes appropriate for healing and resolving inflammation? However, over the last 20 
years, there has been a lack of efficient methods to distinguish infiltrating macrophages and 
local microglia because they are similar morphologically and there is no specific marker to 
characterise their different properties .  
 Recently, blood-derived macrophages were able to be distinguished by using chimeric 
mice in which the host bone marrow cells were replaced by donor green fluorescence 
protein expressing myeloid cells. When these mice were subjected to spinal cord contusion 
injury, blood-derived macrophages were infiltrated on day 3 after the injury and these cells 
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were located around the lesion and did not enter the epicentre of the lesion (Shechter et al., 
2009). When the recruitment of peripheral macrophages were conditionally ablated or 
diminished, spontaneous recovery was lost. Further experiments has suggested that the 
expression of IL-10 from infiltrated macrophages were critical in controlling the 
inflammatory resolution and motor functional recovery (Schwartz, 2010). This study 
highlights the fact that recovery following SCI involves blood-derived macrophage in a 
manner similar to normal wound healing. However, unlike other tissues, the inflammatory 
response fails to resolve itself because of either incapability of resident microglia to provide 
terminating signals and/or insufficient infiltrated macrophages which are able to switch 
from pro-inflammatory (M1) to "alternatively activated" anti-inflammatory (M2) phenotype 
in response to local signals(Detloff et al., 2008, Homsi et al., 2010, Nahrendorf et al., 2007, 
Shechter et al., 2013, Thawer et al., 2013). This transition from M1 to M2 macrophage 
phenotype is important in promoting healing as well as resolving inflammation (Thawer et 
al., 2013). All these experiments shed new light on the role of peripheral macrophages to 
recovery from CNS injuries. 
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2.5  Overview of this project  
 
2.5.1. Vascular endothelial growth factor 
 
Vascular endothelial growth factor (VEGF) was first isolated from tumour cells and 
regarded as the most potent pro-angiogenic factor (Poltorak et al., 2000). It is an endothelial 
cell mitogen and promotes the growth of vascular endothelial cells (Ferrara, 2000, Sondell 
et al., 1999b). It also plays an essential role in blood vessel development in embryos. So far, 
six isoforms of VEGF ranged from 121 to 206 amino acids are produced from single gene 
by alternative splicing(Rosenstein and Krum, 2004). The major differences between 
different VEGF isoforms is their extracellular matrix (ECM) and heparin-binding ability 
(Benton and Whittemore, 2003). For example, VEGF121 is the most soluble isoform and 
does not bind to heparin or extracellular matrix (ECM), whereas VEGF165 binds relatively 
weakly to heparin and ECM (Park et al., 2003, Storkebaum and Carmeliet, 2004). However, 
VEGF165 is the most common isoform in most mammalian tissues (Benton and Whittemore, 
2003, Rosenstein and Krum, 2004).  
Currently, three VEGF receptor (VEGFR) have been identified. They are members 
of the receptor tyrosine kinase family and belong the same subclass as receptors for PDGFs 
and FGF(Nilsson and Heymach, 2006). Of the three receptor, VEGFR 1 is mainly involved 
in developmental angiogenesis and recruitment of haematopoietic precursors, whereas 
VEGFR2 and VEGFR3 are essential for the functions of vascular endothelial and 
lymphendothelial cells respectively (Takahashi and Shibuya, 2005{Uehara, 2013 #16639, 
Uehara et al., 2013). Since VEGFR 2 is expressed on almost every endothelial cells, it is 
believed that VEGFR 2 mediates most downstream angiogenic effect of VEGF (Rini and 
Small, 2005).The binding of VEGF ligands to VEGFR 2 promote angiogenesis by 
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enhancing the endothelial cell proliferation and migration via MAPK/ERK and 
phosphatidylinositol 3-kinase (PI3K) pathway respectively (Thomas and Eichmann, 2013).  
Over the last two decades, the role of VEGF in angiogenesis was the object of 
intense investigation. However, recent reports suggest that new vessel growth and 
maturation are highly complex and regulated processes and require sequential activation of 
signalling pathways as well as many other molecules (Rosenstein and Krum, 2004, 
Takahashi, 2008, Takahashi et al., 2004, Takahashi and Shibuya, 2005). Indeed, acute 
delivery of recombinant VEGF did not increase the angiogenesis at the epicentre of the 
injury despite increased spinal cord tissue sparing, reduced apoptotic cells and mild 
functional improvement (Widenfalk et al., 2003). In that study, VEGF treatment had no 
robust influence on cell proliferation as shown by BrdU labeling indicate that the beneficial 
effects are mainly due to the blood vessel protection and/or effects of VEGF on other non-
vascular component. Also, increased expression of VEGF after SCI resulted in robust early 
vessel growth that recedes at later time-points (Casella et al., 2002, Lopez-Vales et al., 
2004, Vaquero et al., 1999). This suggests that VEGF can initiate angiogenesis but cannot 
sustain blood vessel maturation.  
 In addition to angiogenesis, VEGF plays a role in induction or augmentation of 
inflammation. In the central nervous system (CNS), VEGF can alter blood-brain barrier 
(BBB) permeability and can enhance monocyte infiltration into brain parenchyma via 
VEGF-VEGFR1 signalling pathway (Shibuya, 2006, Yancopoulos et al., 2000). Delivery of 
VEGF into the brain has been shown to induce leukocyte infiltration before angiogenesis 
(Croll et al., 2004). In that study, low doses of VEGF initiated inflammation but not 
angiogenesis, suggesting the pro-inflammatory role of VEGF. VEGF is also a monocyte 
attractant in vitro (Waltenberger et al., 2000) and promotes haematopoiesis in vivo (Hattori 
et al., 2001). VEGF increased the expression of adhesion molecules such as ICAM-1, 
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which encourage leukocyte sticking and rolling in the brain vasculature (del Zoppo, 1997, 
Ment et al., 1997). Recently, it has also been demonstrated that VEGF has neurotrophic 
activity and promotes axonal outgrowth, enhancing axon growth and Schwann cell survival 
in the peripheral nervous system (Figure 2-4) (Sondell et al., 1999a, Sondell et al., 2000). In 
addition, VEGF is involved in axonal growth during CNS development as well as 
promotion of stem cell proliferation (Jin et al., 2006, Jin et al., 2002, Kawakami et al., 
1996). VEGF is also shown to have neuroprotective effect on the spinal cord (Ding et al., 
2005).  
 
Figure 2-4. Schematic diagram showing the effects of Vascular endothelial Growth Factor on different 
cells types in central nervous system. 
(Storkebaum et al., 2004) 
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2.5.2 Platelet-derived growth factor 
 
Although VEGF initiates the angiogenesis process, subsequent blood vessel 
maturation and stabilisation requires other molecules; one of which is Platelet-derived 
growth factor (PDGF). PDGF activates MAPK pathway which mediates smooth muscle cell 
and pericyte6 recruitment to the endothelial lining of nascent vasculature and promotes 
blood vessel stability and maturation (Bezuidenhout et al., 2009, Shih and Holland, 2006). 
Combined delivery of VEGF and PDGF stimulated a prolonged and robust angiogenic 
response in other tissue models (Chen et al., 2007, Richardson et al., 2001). The led us to 
consider dual growth factor delivery to promote angiogenesis after SCI in an attempt to 
reduce secondary degeneration.  
PDGF maintains the proliferation of oligodendrocyte progenitor cells in the spinal 
cord and administration of trapidil, an antagonist of PDGF, reduced the spontaneuous 
remyelination in brain. (Allamargot et al., 2001, Fressinaud, 2005, Lachapelle et al., 2002). 
A single injection of PDGF into the cerebral cortex also accelerates the rate of 
remyelination in vivo (Allamargot et al., 2001). However, the role of PDGF in CNS remains 
elusive. Studies have demonstrated a role for PDGF in neuroprotection during development 
(Heldin and Westermark, 1999) and a role in reducing neuron susceptibility to glutamate 
toxicity in vitro.(Beazely, et al., 2009). However no neuroprotective effect was seen when 
PDGF-BB was delivered directly post-injury in an ischemic model of brain trauma (Iihara, 
et al., 1997) and Enge et al (2003) found no specific effects on  developmental or injury 
when PDGF was genetically ablated in post-mitotic neurons.  .  
                                                 
 
6 Pericyte is a mesenchymal-like cells that associated with the small blood vessels 
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PDGF is also shown to be chemotatic for monocytes and neutrophils (Deuel et al., 
1982, Key et al., 1983). In addition, it is demonstrated that PDGFs and PDGF receptors are 
involved in the growth control and differentiation mechanisms of monocyte-macrophage 
differentiation (Savikko and von Willebrand, 2001). As a result, PDGF may play an 
important role in neuro-inflammation and this pro-inflammatory effect of PDGF as well as 
VEGF might attenuate the inflammatory conditions of the injured spinal cord. However, the 
effect of PDGF on SCI  has not been reported. 
 
 
2.5.3 Objective of this project 
 
Angiogenesis, the growth and remodelling of the vascular network is a crucial step 
during development, growth and tissue regeneration. In SCI, this process seems to be perturbed 
(blood vessels formed initially, later regressing), which results in breakdown of the BSB, a 
prolonged inflammatory response and secondary degeneration (Casella et al., 2006, Casella et 
al., 2002, Rigau et al., 2007).  Therefore, stabilising the angiogenic response is a potential target 
to promote recovery after SCI (Oudega, 2012).  
In this project, we investigated the effects of 2 different approaches which stabilise the 
BSB after traumatic spinal cord injury. The first method involves the treatment of hyperbaric 
oxygen (100% oxygen at high atmospheric pressure ) which helps to reverse the tissue hypoxia 
and stablise the angiogenic response after SCI. The second approach is combined delivery of 
VEGF and PDGF into injured spinal cord.  The synergy of both growth factors is crucial in 
mature blood vessel formation (Richardson et al., 2001). Our hypothesis was that the co-
delivery of VEGF and PDGF would improve intra-lesion angiogenesis and promote the 
maturation of newly formed vessels. We predicted that improving intra-lesion angiogenesis, by 
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hyperbaric treatment or/and VEGF/PDGF delivery,  would restore the blood brain barrier, slow 
down the infiltration of inflammatory cells and provide an environment where neurogenic 
therapies could be readily applied. 
 
 Page 44 
Yun Wai Young 2010 Page 44 
3Chapter 3: Hyberbaric Oxygen Treatment in 
Spinal Cord Injury 
3.1 INTRODUCTION 
 
Traumatic injury to the spinal cord creates an initial physical injury not only to the 
neural cells but also the blood vessels as well as the BSB, which induces prolonged 
inflammatory events leading to secondary degeneration of spinal cord tissue (Beck et al., 2010, 
Fleming et al., 2006, Hausmann, 2003). Accordingly, suppression of the inflammatory response 
remains a therapeutic target and one of the methods that have been applied clinically is 
hyperbaric oxygen treatment (HBOT). In HBOT a patient is exposed to 100% oxygen at greater 
than atmospheric pressure (normally 2-3 ATM) for short period of time (normally 1-2 hr) 
(Huang et al., 2003) . Hyperbaric oxygen is also used to treat hypoxia-related disorders such as 
carbon monoxide poisoning, decompression sickness and refractory osteomyelitis as well as 
ischemic and chronic wounds (Tibbles and Edelsberg, 1996). Therefore, the rationale of using 
HBOT is to reverse the tissue hypoxia and reduce the production of cytotoxic molecules.  
There are several reports of HBOT in spinal cord injury animal models (Lahat et al., 
1995, Murakami et al., 2001, Nie et al., 2006). Although HBOT improved neurological 
outcomes in ischemic injury model, ischemic models do not necessarily recapitulate the tissue 
damage and oedema associated with traumatic injury (Braughler and Hall, 1989, Kahraman et 
al., 2007). In addition, HBOT has been shown to suppress neuro-inflammation and expression 
of matrix metalloproteinase-9 in traumatic brain injury (Vlodavsky et al., 2006). More 
importantly, HBOT reduces reperfusion as well as the expression of intercellular adhesion 
molecule-1 (ICAM-1) on endothelial cells (Buras et al., 2000). Since ICAM-1 plays an 
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important role in leukocyte extravasation, the treatment of HBOT reduces the infiltration of 
leukocytes in injured tissue (Farooque et al., 2001).  
However, the anti-inflammatory effect of HBOT was mainly demonstrated in ischemia-
reperfusion injury (Al-Waili et al., 2005, Gertsch-Lapcevic et al., 1991, Larson et al., 2000, Lee 
et al., 2010, Miljkovic-Lolic et al., 2003, Yin et al., 2002) whilst its role on inflammatory 
response in traumatic SCI is largely unknown. Therefore,  we set up a commonly used 
traumatic SCI animal model known as unilateral  hemisection model. The major advantage of 
this model is that the pathological changes and subsequent neurological outcomes is relatively 
stable after the injury (Stokes and Jakeman, 2002) and the bladder and bowel function is 
normally maintained results in less morbidity for the post-operative animals  (Talac et al., 
2004). The aim of this study is to investigate the effect of HBOT on the rat hemisection model 
of SCI, in particular looking at the inflammatory response at the site of injury. More 
importantly, this study was designed : (1) To examine the effect of HBOT on early 
inflammatory response in traumatic SCI, and (2) To set up the hemisection injury model of SCI 
and to learn post-injury care. (3) To develop and validate methods to characterise the 
morphology and size of macrophages/microglia at the site of injury, which extends our 
knowledge of inflammatory cells on HBOT. 
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3.2 MATERIALS AND METHODS 
 
3.2.1 Animal Surgery 
 
All experiments were undertaken with the approval of the Queensland University of 
Technology Animal Ethics Committee according the guidelines of the National Health and 
Medical Research Council of Australia. Adult male Wistar Kyoto rats were anesthetised by 
intraperitoneal injection of 70 mg/Kg Zoletil 100 (Virbac Animal Health) and 15mg/Kg 
Xylazine (Troy Laboratories Pty Ltd). Complete laminectomies were performed at T10 and 
the animals were subjected to T10 lateral hemisections (left) as previously described (Naso 
et al., 1995). At 1 day post-injury, treatment rats were exposed to 2 hours/day of hyperbaric 
oxygen (100% oxygen, 2 ATM) in a hyperbaric chamber (AIMTEK pty. Ltd, Queensland; 
Fig 3.1) for 14 days. Control animals did not undergo HBOT and they were kept at ambient 
pressure in normoxic air and. Animals were sacrificed at 14 days post-injury. Each group 
had 5 animals. 
 
 
Figure 3-1 The Hyperbaric Chamber used in the study. In treatment group, rats were exposed to the 
hyperbaric oxygen treatment with 100% medical oxygen at 2 ATM for 2 hours/day for 14 days. 
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3.2.2 Histology  
 
At 2 weeks post-injury, rats (n=5) were sacrificed by an overdose injection of sodium 
pentobarbital and perfused transcardially with phosphate-buffered saline (PBS) followed by 
Zamboni’s fixative solution. Spinal cords were dissected out and fixed in Zamboni’s fixative 
solution overnight followed by dehydration with graded ethanol solutions. Spinal cords were 
embedded in polyethylene glycol as described (Schulz, et al., 2004) and sectioned at 40 µm 
with rotary microtome (Leica RM 2255, Germany). The sections were then stained with 
following primary antibodies: rabbit anti-neurofilament 200 (NF200) for axons (Chemicon, 
1:400), mouse monoclonal anti-glial fibrillary acidic protein (GFAP) for astrocytes (Chemicon, 
1:800), and rabbit anti-ionized calcium binding adapter molecule 1 (IBA1) for 
macrophages/microglia (Wako, 1:1000). Sections were then incubated with corresponding 
Alexa Fluor 594 labelled donkey anti-mouse or Alexa Fluor 488 labelled donkey anti-rabbit 
secondary antibodies (Molecular Probes). Sections were mounted with Vectorshield mounting 
media with DAPI (Vector Laboratories). Images were captured using an Axio Imager Z1 epi-
fluorescence microscope with Apotome and an Axiocam Mrm camera (Carl Zeiss, Germany) 
 
3.2.3 Quantification of lesion size  
 
The size of the lesion was measured from the mid-line section determined by the 
presence of the central canal as well as by measurement of half thickness of the tissue specimen 
at the injury level. There was occasionally a discrepancy between these two indicators due to 
minor variations in the orientation of the cord during embedding, in which case we used the 
latter direct measurement of the slice position. Each tissue specimen was inspected to ensure it 
was damage free, and stained for GFAP and NF200. This was repeated for each of the five 
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animals in both treatment and control groups. After staining, nine adjacent images were taken at 
the lesion site and surrounding tissue using a 10x objective. These were combined into a single 
image using AxioVision 4.7 (Carl Zeiss, Germany) and fluorescent images were compiled for 
both secondary antibodies in order to define the lesion cavity size by the margin of NF200 and 
GFAP immune-reactivity. This margin was measured by using the surrounding the border of 
the immune-positive area with the AxioVision ‘measure’ tool by a blinded observer. The 
measurements of the midline lesion area were averaged over all animals in either group.  
 
3.2.4. Identification and quantification of IBA1 positive cells at different stages 
 
To study the inflammatory response, macrophages and microglia which were stained 
with IBA1 antibody were examined at 200 µm from the edge of lesion border identified by 
GFAP staining (Figure 6-2). Counting was performed using the set of 3D stereological rules 
described by Williams and Rakic (1988). Briefly using a 20x objective, five fields of view 
300x300 m2 z-stack images (5 x 3 µm) in each of five tissue sections taken from absolute 
midline section of the horizontally sectioned cord (n=5 fields per animal; 5 animals per group). 
In each of these fields, the images were reconstructed so that the whole cell morphology can be 
observed. In each of these fields the total number of Iba immuno-positive cells were counted, 
and the size of the cell body measured using the AxioVision ‘measure’ tool by a blinded 
observer. The morphologies of the IBA1 immunopositive cells were classified based on cell 
body size are into resting, generally showing a small ramified appearance with a cell body 
cross-sectional area of 20-30mm2; primed / activated with larger cell bodies 30-150mm2 and 
generally with no or few thick processed and phagocytic, very large with a cell body area 
greater than 150mm2, without processes.  
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Figure 3-2. Macrophages and microglia (IBA1 positive cells) were examined at 200 µm from the edge of 
lesion border identified by GFAP staining. Five fields of view 300x300 m2 z-stack images (1-5; 5 x 3 µm) 
were used  
 
3.2.5 Statistical Analysis 
The data are presented as mean ± standard errors. Statistical comparison of the mean 
was performed using Student’s t-test (Sigma Plot 11) with the α-value of 0.05 accepted as 
significant.    
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3.3 Results 
 
3.3.1.Histology and Quantification of lesion size  
 
At 2 weeks post-injury, the effect of HBOT on injured spinal cord was assessed by the 
immunofluorescence. Figure 3.2 shows the representative fluorescence images, stained with 
axonal (NF200) and astrocytes (GFAP) antibodies, of the lesion sites in HBOT treated animals 
(Figure 3.2 A & C) and control animals (Figure 3.2 B & D). No morphological difference was 
observed between treatment group and controls.  
The mean lesion cavity size for NF was 0.23 ± 0.07 mm2 and 0.32 ± 0.12 mm2 for 
hyperbaric oxygen treated animals and lesion controls respectively (p=0.538) (Figure 4.2 E). 
The mean lesion cavity size for GFAP was 0.28 ± 0.09 mm2 and 0.44± 0.09 mm2 hyperbaric 
oxygen treated animals and lesion controls respectively (p=0.212). Although a smaller lesion 
cavity size was observed in treated animals, this was not significant  for either NF200- or 
GFAP- defined lesions.  
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Figure 3-3. Treatment of hyperbaric oxygen did not alter the size of the lesion in hemisectioned spinal 
cord . A-D Representative immunofluorescence images co-stained with neurofilament 200 (NF200) for axons 
and glial fibrillary acidic protein (GFAP) for astrocytes from hyperbaric oxygen treated (HBOT; A & C) and 
controls (B & D) spinal cords. E: Quantification of lesion cavity size from HBOT treated animals and control 
with the margin defined by NF200 and GFAP (Mean ±SD; n=5). No significant difference was detected 
between the HBOT treatment group and controls. 
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3.3.2. Characterisation and quantification of IBA1 Immuno-positive cells 
 
To study the immune response, macrophages /microglia, labelled with IBA1, were 
examined at 200 µm from the edge of GPAP border. At 2 weeks after injury, there was a 
robust IBA1 expression around the lesion site in both HBOT and control animals (Figure 
3.3 A-B). However, higher magnification images (20 X objective) at 200µm from the edge 
of lesion demonstrated a reduction in the IBA1-positve cells in HBOT animals compared to 
controls (Figure 3.3 C-D). Since the size and morphology of microglia and macrophages 
alter when they are in difference stages of activation (Sheng et al., 1998, Stence et al., 
2001), IBA1 positive cells were characterised and classified into three different subtypes as 
mentioned before (Figure 3.3E).    
We then quantified the distribution of morphological types along a perimeter of 200 
µm from the edge of the GFAP-defined margin. In HBOT animals there was a significant 
reduction in the total number of IBA1 positive cells with an activated morphology when 
compared to controls (HBOT: 830± 54 cells/mm2; Control: 1576± 82 cells/mm2; p<0.001) 
(Figure 4.3F). There was also a significant reduction in the number of cells with a primed 
state (HBOT: 237± 30 cells/mm2; Control: 541± 54 cells/mm2; p<0.001). No inter-group 
differences were detected with cells of the other morphologies (i.e. resting and phagocytic). 
In contrast to other studies (McKay et al., 2007) , we did not observe a mark morphological 
difference of IBA1 positive cells between the grey matter and white matter (See Appendix) 
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Figure 3-4.Treatment with hyperbaric oxygen reduced extravasation of macrophages/microglia.  A-B: 
Representative IBA1 immunofluorescence images of the lesions from hyperbaric oxygen treated (A) and 
Control (B). C-D. High magnification (20X; Z-stack reconstructed images) views of area seen in the box (200 
µm from lesion) in previous figures confirm that reduced accumulation of macrophages/microglia in 
hyperbaric oxygen treated animals when compared to controls. E Macrophages /microglia were classified into 
4 different subtypes based on their size and morphologies. F. IBA1-positive cells were grouped in 4 
phenotypes and the number of each phenotype was measured 200μm from lesion. A statically significant 
difference was detected on total population of IBA1-positve cells between the hyperbaric oxygen treated 
group and control (Ptotal<0.001). In addition, the increased IBA1 positive cells were all in either an activated or 
primed cell type with statistically significant elevation in both of these phenotypes. (Pactivated<0.001, 
Pprimed<0.001). No significant difference was detected on population of either resting or phagocytic phenotype 
between the hyperbaric oxygen-treated cord and control. (n=25 fields per animal; 5 animals per group) 
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3.4 Discussion 
 
The effect of HBOT on inflammatory response on traumatic SCI remains elusive . 
Despite its clinical application in SCI, most of its scientific justification has been based on 
ischemic models which might not necessarily recapitulate the cellular response that results from 
traumatic SCI.   Therefore, in this chapter, we have set up a reproducible traumatic SCI animal 
model (lateral hemisection) which has similar histological change and lesion cavity observed in 
other studies (Bennett et al., 1999, Filli et al., 2011, Hsu and Xu, 2005, Hulsebosch et al., 
1984a, Hulsebosch et al., 1984b, Lukacova et al., 2006, Xu et al., 2000). With the use of this 
model, it was demonstrated that HBOT has mild anti-inflammatory effect with significant 
reduction of total number of macrophages/microglia at the lesion site at 2 weeks post-lesion. 
These findings are similar with other HBOT studies using ischemia-reperfusion brain injuries in 
which the adhesion of leukocytes was impaired (Larson et al., 2000, Miljkovic-Lolic et al., 
2003). This observed reduction of immune cells may be due to a combination of two 
mechanisms. (1) Hyperbaric oxygen treatment has been shown to reduce oedema in many 
conditions, which is thought to be mediated by vasoconstriction and reduction blood flow 
(Mink and Dutka, 1995, Xu and Huang, 1991). The blood-flow reduction and systemic 
vasoconstriction resulted in reduced extravasation of blood circulating inflammatory cells. (2) A 
recent study has demonstrated that hyperbaric oxygen down-regulates expression of the 
endothelial cell adhesion protein, ICAM-1, which is an important ligand for leukocyte rolling 
(Buras et al., 2000). Also, HBOT inhibits the function of beta-2-integrin dependent adherence 
of leukocytes (Thom et al., 1997). All these factors may contribute to the reduced inflammatory 
cell population in the damaged tissue. 
At the lesion edge, a mixed population of IBA1-positive cells with distinct 
morphologies were observed. However, the identification of the inflammatory states of these 
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cells has been difficult due to lack of specific markers (Schwartz, 2003, Schwartz, 2010), 
dynamic change of inflammatory cells in response to microenvironment alternation (David and 
Kroner, 2011, Salegio et al., 2011), and large scale tissue harvesting (Graber et al., 2010).  
Since the morphology and size of macrophage/microglia is the indication of its activation stage, 
we characterised the accumulated cells into three different subtypes ranging from resting to 
primed/activated to phagocytic  based on their size and morphology (Sheng et al., 1998).  The 
distribution of morphological types was then quantified along a perimeter of 200 µm from the 
edge of the GFAP-defined margin. This quantification allows us to examine the tissue response 
in the same way (same distance from the lesion edge) and compare the distributional difference 
of morphological types between the HBOT and controls. The treatment with hyperbaric oxygen 
significantly reduced the population of macrophages/microglia at both primed/activated stages 
when compared to control treatment suggesting a reduced infiltration of peripheral 
macrophages or a decreased activation of local microglia. No inter-group differences were 
observed with cells of other morphologies. However, unlike other reports using ischemic-
reperfusion injury, we did not observe a significant reduction in lesion volume two weeks after 
injury. This may be related to the severity of the injury produced in different animal models. 
The dorso-lateral hemisection model used in this study produces a more severe injury with a 
larger amount of tissue damage resulting in breakdown of BSB, significant oedema, and 
massive influx of circulating inflammatory cells when compared to ischemic injury (Bouyer, 
2005, Kastner and Gauthier, 2008, Nesathurai et al., 2006, Talac et al., 2004).  
The beneficial effects of HBOT in CNS were mostly reported in mild ischemia-
reperfusion animal model where there is no significant initial tissue damage and/or physical 
breakdown of BSB (Asamoto et al., 2000, Dong et al., 2002, Hjelde et al., 2002, Miljkovic-
Lolic et al., 2003). In the absence of monocyte infiltration, the tissue damage (necrosis) and 
inflammation, including activation of local population of microglia are mainly driven by 
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hypoxic conditions in the tissue (Kim et al., 2003b). In this situation, treatment providing pure 
oxygen at high pressure may alleviate hypoxic conditions which in turn reduces the 
inflammatory response and cell death from ischemia. However, in traumatic SCI such as the 
hemisection model, the majority of secondary degeneration is directly attributed to a complex 
and multifaceted inflammatory response. This inflammatory response involves not only the 
activation of microglia and hypoxia but also the infiltrated macrophages and associated 
cytokines such as TNF-α and IL-1. In this situation, alleviation of tissue hypoxia alone might 
not be enough to reverse the tissue degeneration because the inflammation is significantly 
driven by inflammatory cytokines (Hayes et al., 2002). It is further demonstrated by a study 
carried out by Hjelde et. al.(2002), in which HBOT provided no reduction of tissue damage in 
permanent focal cerebral ischemia, which produces a more severe insult than other ischemic-
reperfusion animal models. 
We did not observe any significant reduction of lesion cavity size even though the total 
population of macrophages/microglia were reduced, similar to other immune-suppressive 
approaches for treating SCI. These anti-inflammatory therapies include olomoucine and anti-
CD11d antibody, which inhibit microglial proliferation and limit neutrophil and 
monocyte/macrophage extravasation respectively (Bao et al., 2005, Oatway et al., 2005, Tian et 
al., 2007a). Both olomoucine and anti-CD11d resulted in functional gains also without large 
histological improvement. This suggests that the behavioural improvement may be due to 
increased axon sparing perhaps by limiting the cytotoxic effect of early regulated inflammation. 
However, the inflammatory response remained unresolved thereby leading to accumulation at 
the lesion site of damaged cells and oxidised extracellular matrix proteins leaving the 
microenvironment neuro-inhibitory (Alexander and Popovich, 2009). As such, anti-
inflammatory therapies seem to be a ‘stopgap’ approach that can slow secondary degeneration  
without initiating a true regenerative capacity.  
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The role of inflammation in SCI remains controversial. Despite extensive experiments 
that suggest that inflammation is detrimental in SCI, inflammation also has a neuroprotective 
role and is pivotal for repair of other tissues (Donnelly and Popovich, 2008). In agreement, 
there is mounting of evidence suggesting that the inflammatory response in SCI is unresolved, 
thence causing secondary tissue destruction. One of the possible reasons for the unregulated 
inflammatory response might be insufficient recruitment of peripheral or blood-derived 
monocytes/ macrophages into the lesion site (Schwartz et al., 1999, Schwartz and Yoles, 2006). 
This specific type of monocyte/macrophage possess the characteristics of M2 or tissue repairing 
macrophages which help to resolve inflammation and promote tissue repair (Schwartz, 2010). 
In this chapter, we demonstrated that the limited extravasation of blood-derived monocytes, 
exerted by HBOT, did not reduce the lesion volume.  
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3.5 Conclusion 
 
In this chapter,  a traumatic spinal cord hemisection model has been established. By 
using this model,  It was demonstrated here HBOT had a mild anti-inflammatory effect on 
traumatic injury by reducing the number and activation of macrophages/microglia at the lesion 
margin. However, we did not observe lesion volume reduction, which suggests that inhibiting 
monocyte extravasation may not be beneficial. We also emphasise that hypoxia is not the only 
mechanism in driving the post-injury inflammation that leads to secondary degeneration after 
traumatic spinal cord injury. However, a more detailed study would be needed in order to 
understand the effect of HBOT on the injured spinal cord, though the lack of obvious 
effectiveness does not make this a very attractive option for future clinical translation. 
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4Chapter 4: Reduction of secondary 
degeneration by acute delivery of VEGF+PDGF 
via hydrogel patch 
4.1 INTRODUCTION 
 
Angiogenesis is a crucial process in tissue repair process (Cuadros et al., 1993). 
However, in SCI, this process is perturbed, which corresponds with  prolonged disruption of 
BSB and inflammation resulting in extended production of neurotoxic molecules which 
ultimately cause the extensive lesion enlargement and astrocytic scarring (Hill et al., 2001). 
Therefore, local angiogenesis is a potent target for therapeutic intervention. 
VEGF is one of the most potent stimulator of angiogenesis and the expression of VEGF 
increased only for a short period of time and then reduced after SCI (Herrera et al., 2009) . As 
such, a range of VEGF therapies have been emerged in treating SCI. Acute delivery of 
recombinant VEGF or cells overexpressing VEGF resulted in reducing tissue loss and ischemic 
cell death and improving behavioral outcomes (Kim et al., 2009, Widenfalk et al., 2003). 
However, in the these studies, VEGF did not increase angiogenesis at the epicenter of the 
injury, which might possibly be due to the lack of mature vessel formation (Casella et al., 2002, 
Yancopoulos et al., 2000). Although VEGF can initiate angiogenesis, other factors are usually 
required for mature vessel formation; one of these is PDGF. PDGF has been shown to stimulate 
smooth muscle cell recruitment and promote blood vessel stability and maturation (Liu et al., 
2006). When both growth factors were delivered into ischemic muscle, a prolonged and robust 
angiogenic response was stimulated (Chen et al., 2007, Hao, 2007). This led us to consider dual 
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growth factor deliver to promote angiogenesis after SCI in an attempt to reduce secondary 
degeneration.  
  In this study, a polymer gel was developed and optimised so that VEGF and PDGF can 
be delivered to the site of injury over a short period of time (within 48 hours). It was expected 
that sustained delivery of high dose of VEGF and PDGF would promote better angiogenesis 
and neuroprotective effect when compared to bolus injection (Chen et al., 2007, Patel et al., 
2009, Yasuhara et al., 2005). Since both growth factors target several inflammatory cells and 
promote vascular perfusion (Dhillon et al., 2007, Kataru et al., 2009, Rosenstein and Krum, 
2004), the effect of VEGF+PDGF on macrophages/microglia was also investigated. 
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4.2 MATERIALS AND METHODS 
 
4.2.1 Preparation of drug delivery patch 
 
5 µg of recombinant human VEGF-165 (Invitrogen) and 5 µg of recombinant mouse 
PDGF-BB (Invitrogen) were dissolved in 40% (w/w) of Pluronic F127 (Sigma). These 
solutions were then mixed with 50% (w/w) polyethylene glycol-8000 (PEG-8000; Sigma), 
polyethylene glycol diacrylate (Sigma) and ddH20. This was mixed with 0.5% w/w 2,2-
Dimethoxy-2-phenylacetophenone (photoinitiator; Sigma) and were pipetted 30 µl into a 
5mm x 5mm silicone mould. The patches were polymerised under ultraviolet light by using 
UV lamp (Omnicare series 1000; power: 80%) for 1 min. Another 20µl of backing gel 
solution containing 50% w/w of PEG-8000 and polyethylene glycol diacrylate together with 
photoinitiatior was added on top of drug delivery gel and allowed to photopolymerise for 1 
min. The patch was stored at -20C until needed. 
 
 
 
Figure 4-1.Schematic diagram illustrates the implantation of the drug delivery gel onto the injured 
spinal cord of rat. Release of the vascular growth factor was restricted to the lesion site as indicated by 
purple 
Spinal cord 
Lesion site 
Drug delivery gel 
Backing gel 
VEGF
PDGF 
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4.2.2  Quantification of VEGF+PDGF released from the patch 
 
Individual drug delivery patch implants were placed in 1ml PBS at 37°C. Samples 
were collected by pipetting the entire 1 ml from the implant and replacing it with fresh PBS. 
This was performed between 1 and 240 hours. The total concentration of VEGF and PDGF 
released were determined using VEGF (Quantikine®, R & D system, Inc) and PDGF 
(Quantikine®, R & D system, Inc) ELISA kits, respectively, according the manufacturer’s 
instruction. The experiment was repeated three times. 
 
4.2.3 Animal Surgery for patch implantation 
 
Approval was gained from the Queensland University of Technology and the Griffith 
University animal ethics committees.  Adult male Wistar rats were anesthetised with 
intraperitoneal injection of 70 mg/Kg Zoletil 100 (Virbac Animal Health) and 15mg/Kg 
Xylazine (Troy Laboratories Pty Ltd). Complete laminectomy was performed at T10 and the 
animals were subjected to T10 hemisection as previously described (Teng et al., 2002). 
Animals were randomised to a treatment group (Lesion Control (LC), Gel Control (GC) and 
Active Gel (AG)) after the spinal cord was cut. Each group had 6 animals 
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Figure 4-2. Implantation of gel after spinal cord hemisections 
 
4.2.4 Tissue dissection and processing and immunohistochemistry  
The animals (6 rats per groups) were sacrificed at 1 and 3 months .It was carried out by 
injection of an overdose of sodium pentobarbital and the spinal cords were dissected from 
the spinal columns as described above (Section 3.2.2). Sections were processed and stained 
with antibodies listed in table 4-1. Stained sections were mounted with Vectorshield 
mounting medium (Vector Laboratories). 
Primary Antibody  Stain for   Company  Dilution
Mouse anti‐neurofilament 200 (NF 
200)  Neurofilament  Chemicon  1/1000 
Rabbit anti‐glial fibrillary acidic protein 
(GFAP)  Astrocyte  Chemicon  1 /1000 
Mouse anti‐smooth muscle actin 
(SMA)  Blood vessel  Chemicon  1/400 
Rabbit anti‐ionized calcium 
binding adapter molecule 1(IBA 1)  Macrophage/Microglia  Wako  1/ 500 
 
Table 4-1. List of antibodies used in this study.  
Secondary Antobody  Company   Dilution
Alexa Fluor ®488 labelled Donkey anti‐rabbit antibody  Molecular Probes  1/400 
Alexa Fluor ® 594 labelled Donkey anti‐rabbit antibody  Molecular Probes  1/200 
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4.2.5 Quantification of lesion cavity size  
 
The size of the lesion was measured from the mid-line section determined by the 
presence of the central canal as well as by measurement of half thickness of the tissue 
specimen at the injury level. This tissue specimen was inspected to ensure it was damage 
free, and stained for GFAP and NF200 as mentioned in section 3.2.3. This was repeated for 
each of the five animals in each group (n=5).  
 
4.2.6 Quantification of microglia/macrophages at the lesion margin 
 
To study macrophages/microglia, Z-stack mosaic images (large images that are 
reconstructed from higher magnification multiple-image taken at multiple sites on the 
sample and provide a detailed view of large area of specimen)  were taken at 200µm from 
the edge of the GFAP-defined lesion. Counting was performed using the set of 3D 
stereological rules described by Williams and Rakic (Williams and Rakic, 1988). Briefly 
using a 20x objective, five optically defined counting boxes 300x300x25 µm3 were 
identified around this perimeter in each of five tissue sections taken from directly dorsal and 
ventral of the absolute midline section of the horizontally sectioned cord (n=25 fields per 
animal; 5 animals per group). In each of these fields the total number of IBA1 immuno-
positive cells were counted, and the size of the cell body measured using the AxioVision 
‘measure’ tool. Cells were only measured if they were entirely contained within the box or 
intersected the top, rear or right optical planes. The morphologies of the IBA1 immuno-
positive cells were classified based on cell body size are into resting, generally showing a 
small ramified appearance with a cell body cross-sectional area of 20-30　m2; primed / 
activated with larger cell bodies 30-150 　m2 and generally with no or few thick processed 
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and phagocytic, very large with a cell body area greater than 150　m2, without processes 
(Figure 4-3). 
 
Figure 4-3. The morphologies of microglia/macrophages were classified into three different subtypes 
according to their sizes and morphologies. 
 
4.2.7  Gliosis and macrophage/microglia density measurement 
 
Gliosis and macrophage/microglia denstity were quantified using a previously described 
and validated image analysis method (Romero-Sandoval et al., 2008). 
Specifically, the pixel intensity of GFAP and IBA1, Z-stack images (3 µm * 5 slices) were 
taken at 200µm away from the lesion site (at least 5 positions per slide). Fixed exposure 
times were used for taking the images (i.e., 40ms for GFAP and 80ms for IBA1). Images 
were imported into Photoshp CS2 without altering image qualities such as colour and 
brightness. A 200 µm * 200 µm box ( ¼ of the original image) was cropped from the 
original images to avoid vessels or autofluorescence and the cropped images were analysed 
using MatLab  embedded with Image Processing Toolbox 6.2 with the threshold intensity of 
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10 (>10 = Bright; <10 Dark). Data were presented as percentage of bright pixel in the whole 
cropped images. All image data was subjected to manual verification and analysed by using 
Sigma Plot 9.0. 
 
4.2.8. Quantification of blood vessel density 
 
Blood vessel density was determined 1 month after injury from sections derived from 
active gel-treated, lesion control only and uninjured spinal cords.  These sections were obtained 
from 140µm ventral to the midline and stained with antibodies to GFAP and SMA to determine 
the lesion margin and blood vessels respectively. Images were taken 200µm from the GFAP 
defined lesion margin and the area of tissue staining positive for smooth muscle actin was 
measured manually using Axiovision 4.7 (Carl Zeiss, Germany). The measurement was 
repeated at four locations around the lesion margin for each animal and the density was 
determined as the percentage of the overall field of view. The percentage was then averaged 
across treatment groups and the differences in the mean blood vessel density were tested using 
ANOVA. 
 
4.2.9 Behavioural tests 
 
The functional recovery of hindlimb was evaluated using Basso, Beattie, Bresnahan 
locomotor rating scale (BBB) (Basso et al., 1995). The recordings were performed 
independently by two trained observers who were blinded to the experimental groupings. 
Animals (n=6) were placed on a circular arena with a non-slippery floor and, during the course 
of 5 min, the hindlimb locomotion was graded from 0 (no observable hindlimb movement) to 
21 (normal movement with parallel paw placement). Behavioural analysis was performed by 2 
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trained investigators who were blinded to the treatment. Paw placement and slip analysis was 
performed using ladder test. In brief a ladder, with mirror installed beneath it, was inclined at 45 
degrees and rats were allowed to climb for 100 rungs (1 metre) for several trials. The climbing 
was recorded on video and later, the placement of the left (affected) paw on the rung during the 
weight bearing phase was scored from 0 to 5 (0: total miss; 1: deep slip; 2: slight slip; 3: 
Correction or replacement (paw position changed after placement or the rung aimed for is 
changed during approach; 4: Partial placement (toes or dorsal sole in contact) and 5 : Correct 
placement (plantar sole in contact)). During the ladder test, the slip frequency occurred during 
the withdrawal of the paw from the rung was also scored from 1 to 4 (1: deep slip; 2: Medium 
slip along the dorsal sole; 3: Paw slip (not beyond the plantar area of the foot) and 4: no error) 
(Sedy et al., 2008).  
 
4.2.10 Statistical Analysis 
 
Data obtained from 6 rats per group at each time point were analysed and all analyses 
were carried out using SigmaPlot 9.0 (Systat software Inc). ANOVAs were used for lesion 
cavity size measurements with post-hoc analysis of significant differences performed using the 
Fisher LSD (α=0.05). For GFAP density comparison, a Kruskal-Wallis ANOVA on ranks was 
performed and post-hoc analysis was carried out using Dunn’s Method (α=0.05). An ANOVA 
was performed to examine the differences between treatment groups in terms of 
microglia/macrophage populations. Post-hoc analysis of significant differences was performed 
using the Fisher LSD (α=0.05). The BBB scores and ladder test data were analysed by ANOVA 
with post-hoc analysis of significant differences performed using the Fisher LSD (α=0.05). 
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4.3   Results 
4.3.1 In vitro quantification of VEGF and PDGF from the drug delivery implant 
 
To estimate the in vivo release of VEGF and PEGF from the implant, in vitro release 
testing was carried out. Both VEGF and PDGF had similar release curves from the patch 
(Figure 4-4). A burst release of the growth factors was observed in the first 10 hours and 
approximately 70% of the growth factors were delivered within 80 hours. It is expected that the 
in vivo release pattern would approximate the in vitro release profile (Silva and Mooney, 2007). 
 
 
Figure 4-4. The release profile of VEGF and PDGF from implant (n=3). 
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4.3.2 Histology and lesion cavity size quantification   
   
To evaluate the effect of the combined delivery of VEGF and PDGF, we performed a 
lateral hemi-section of the thoracic spinal cord at T10 level of Wistar rats. Animals were 
randomised into active gel group (a implant containing 5µg of VEGF and 5 µg of PDGF 
applied to the lesion site); gel control group (a implant without growth factors applied to the 
injury site) and lesion only control (no gel was implanted). At 1 and 3 months post-lesion, 5 
animals from each group were sacrificed and lesion areas were assessed using 
immunofluoresunce with NF-200 and GFAP antibodies.  
At 1 and 3 month post-injury, we observed a dramatic histological differences 
between active gel group and lesion control groups and significantly smaller lesion cavity 
sizes were detected in treated group (Figure 4-5 a-d). The lesion cavity sizes were also 
quantified in two ways by defining the margin of axons using NF200 and by the margin of 
astrocytes using GFAP antibody. Based on the NF200 measurement both gel control and 
lesion control groups showed a significantly larger lesion cavity at 3 months when 
compared to 1 month post-injury, indicating the effects of secondary degeneration (Figure 
4-5e). However, there was no increase in size (NF200) between the active gel groups 
between one and three months demonstrating reduced secondary degeneration. Also, the 
lesion cavity sizes of treated group were significantly smaller than the controls group at 
both 1 and 3 months post-injury (active gel (1 M) vs gel control (1M), p=0.017;  active gel 
(1M) vs lesion control, p=0.025; active gel (3M) vs gel control (3M), p=0.026 & active gel 
(3M) vs lesion control (3M), p=0.021). There was no significant difference between the two 
controls groups at both 1 and 3 month timepoints indicating the implant alone played no 
role in affecting the lesion cavity size when defined by NF200.  
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When the size of the lesion was defined by the GFAP margin there was no 
difference between any of the groups at one month. At three months post injury the active 
gel group was significantly smaller than the controls (p=0.007) which appeared to be 
progressively increasing size similar to the NF200 measurements.  
 
Figure 4-5 Delivery of VEGF+PDGF reduced the secondary degeneration after acute spinal cord injury. 
(a-d) Representative histological Mosaicx of sections obtained from lesion control group (a-b) and 
VEGF+PDGF treated group (c-d) and the central canals are indicated by arrows. Measurement of the spinal 
cord lesion cavity size at one and three month with the lesion margin defined by axons (anti-NF200; e) and by 
astrocytes (anti-GFAP; f) margin. Data are presented as mean±SEM and statistical comparison were 
performed using ANOVA (P<0.05).  
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4.3.3 High magnification immunofluoresence images at 1 Month 
 
A closer examination of the lesion site 1 month after injury in treatment animals reveals 
that there was an accumulation of macrophages/microglia (IBA1- positive cells) at the lesion 
cavity in the treated animals at 1 month (Figure 4-6a). At the same time, the lesion was filled 
with neurofilament-200 (Figure 4-6b) extending beyond the lesion margin as defined by 
GFAP(Figure 4-6c). Conversely, control defects were void of cells at 1 month with the presence 
of a typical cystic cavity that forms post-hemisection.  
 
 
Figure 4-6. Combined VEGF+PDGF treatment increased axon infiltration as well as 
macrophage/microglia accumulation at lesion site. At 1 month after injury, the centre of lesion site of the 
active gel treated animals (as defined by GFAP immunoreactivity (c) was filled with macrophages/microglia 
(a, IBA1 immunoreactivity) and NF200 immunoreactivity (b). In contrast, lesion control animals resulted in 
cavities that were void of both IBA1- positive cells (d) and NF200 (e)  at 1 month. 
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4.3.4. Quantification of IBA1-positive cell around the lesion margin 
 
To investigate the inflammatory response, phagocytes (resident microglia and 
macrophages derived from the circulating monocytes), immunoreactive for IBA1, were 
examined along the circumference (200 µm) from the edge of the GFAP-defined lesion. At 
high magnification (63X), stark differences were observed in the gross morphology of 
phagocytes between the active gel and control groups at both 1 and 3 months post-lesion 
(Figure 4-7). More branched IBA1 positive cells of moderate size were observed in controls 
(Figure 4-7 c & d) while the phagocytes in active gel group appeared to be larger with minimal 
processes (Figure 4-7 a & b).  
 
In the previous chapter, we classified the IBA1 positive cells into three different 
subtypes by using their size and morphology, used to represent the activation state of 
macrophages and microglia. We classified these cells into resting, showing a small ramified 
appearance with a cell body area of 20-30 m2; primed/activated, with larger cell bodies 30-
150m2 and few thick processes; and phagocytic, very large with a cell body area greater than 
150m2, without processes. At one month post-injury there were significantly fewer 
primed/activated cells in the active gel group when compared to the control. (p<0.001) 
Conversely, the active gel group had significantly more phagocytic cells. (p<0.013) 
Proportionally, this means that at one month post-injury 29.5% of the total cell population were 
phagocytic in the treatment group compared with just 8.5% in the control. At 3 months the 
results were similar with the treatment group having significantly fewer primed/activated cells 
(p<0.001) and more phagocytic cells (p<0.001) when compared to the lesion controls. The 
proportion of phagocytic cells was 47.5% in the treatment group, compared with only 13.5% in 
the control.   
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Figure 4-7. Treatment with VEGF+PDGF promoted the resolution of inflammatory response. a-d: 
Representative ionized calcium binding adapter molecule 1 (IBA1) recontructed z-stack immunofluorescence 
images taken from 200µm from spinal cord harvested from controls (a-b) and treatment (c-d) at both 1 & 3 months. 
e-f: IBA1 positive cells were classified into 3 different subtypes based on their size and morphologies and density of 
each subtype was measured at 1 month (e) and 3 months(f). At 1 month post-injury, significant differences were 
detected between the treatments and controls for both activated (p<0.001) and phagocytic subtypes (p=0.013). 
There was an also significant difference between all the class between the treatment and controls at 3 months. 
(Resting, p<0.001; primed, p=0.004; activated, p<0.001 and phagocytic, p<0.001). Data was obtained from 
measuring IBA 1 positive cells at five 300x300x25 µm3  counting boxes at the edge of lesion in each sectioned 
spinal cord and 5 tissue sections were used per animal (n=25 fields per animal; 5 animals per group). 
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4.3.4 Quantification of astrogliosis 
 
Since glial scaring is one of the major obstacles for neuro-regeneration after SCI, we 
examined astroctytic gliosis by measuring the density of astrocytes within the spinal cord along 
a circumference of 200µm from the edge of the GFAP-defined lesion. Morphology of 
astrocytes is an indication of their reactivity (Sheng et al., 1998). Normal unreactive astrocytes 
exhibit the star-shape morphology with multiple thin processes. After SCI, astrocytes become 
reactive with an enlarged cell soma together with thicker and shorter processes, forming a 
physical barrier around the lesion site.  
 At both 1 and 3 months after inujury, reactive astrocytes (Figure 4-8a-b) were clearly 
observed in the lesion control group while astrocytes in treatment group were less activated and 
some of them even exhibited resting morphology (Figure 4-8 c-d). We also performed a 
quantitative image analysis by measuring the GFAP positive pixels in each image which 
represented the area of local astrogliosis (200µm from the lesion edge). At 3 months, the 
percentage of GFAP-immuno-positive area was significantly reduced in treatment group as 
compared to the controls (Figure 4-8e; p<0.05). A reduced number of GFAP-positive pixels 
was detected in 3 month treatment group compared with the one month treatment group 
(p<0.05). All the above results suggest that the VEGF+PDGF treatment reduce glial scaring and 
provided a more neuro-permissive microenvironment after SCI. 
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Figure 4-8 VEGF+PDGF treatment reduced astrogliosis. a-d: Representative images of GFAP 
immunoreactivity at 200µm from the lesion site margin of treated (c-d) and control (a-b) spinal cord at 1 and 3 
months after injury. e: Quantification of the area occupied by GFAP-positive cells using image analysis. At 3 
months post-injury, there was significant reduced area of GFAP-positive pixel in the treatment group when 
compared to controls (p<0.005; ANOVA by ranks) (Whiskers 95% CI).  
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4.3.5 Blood vessels quantification 
 
Since both VEGF+PDGF have been known to induce angiogenesis, smooth muscle 
actin (SMA) antibody, a marker that labelled the blood vessels, were also used in sections from 
active gel treated (Figure 4-10a), lesion control only(Figure 4-10b) and uninjured (Figure 4-
10c) spinal cords. Increased angiogenesis was observed in at the lesion site of lesioned groups 
(treatment and lesion control) when compared to unlesioned control group. Quantitative 
analysis of SMA also revealed that there was significant increase in blood vessel density in 
treatment and lesion control groups when compared to uninjured spinal cord (p=0.009). 
However, there was no significant effect of VEGF+PDGF delivery on blood vessel density in 
the presence of a lesion. 
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Figure 4-9 Combined VEGF and PDGF delivery did not increase blood vessel density over control. At 1 
month post-injury, sections were examined for SMA immunoreactivity and images were taken 200 µm from 
GFAP-defined lesion from spinal cord harvested from treatment group (a), lesion control group (b) and uninjured 
spinal cord (c). (d) Quantification of blood vessel density demonstrated no difference between treatment and lesion 
control, but that both were elevated compared to uninjured tissue. 
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4.3.6 Behavioural analysis  
 
The functional recovery of the rats was evaluated using the Basso, Beattie, and 
Brensnahan (BBB) open-field test. There was no significant difference between treatment and 
controls groups at both 1 and 3 month periods (p=0.80) (Figure 4-11). At one month post-
injury, the BBB scores of lesion control, gel control and treatment groups were 9.6 ± 2.7, 10.2 
±2 and 8.2±1.8 respectively. The BBB scores remained steady at 3 month time-points (11.5±3.3 
in the lesion control, 10.3±2 in the gel control and 9.6±0.2 in the treatment group). There was 
no significant difference in any group between the 3 month and 1 month periods. 
In the ladder climbing test, there was no significant difference between treatment and 
controls groups at both 1 and 3 month periods in term of paw placement as well as paw slip 
frequency by using Kruskal-Wallis tests (Figure 4-12 and 4-13). 
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Figure 4-10 Acute VEGF and PDGF delivery did not improve the functional recovery. Basso, Beattie, and 
Bresnahan (BBB) open-field behavioural test was performed on lesion control, gel control and treatment groups 
(n=6) at both 1 and 3 months time-points. No significant difference was detected between treatment and control. 
(Mean±SEM).  
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Figure 4-11. The paw placement analysis between treatment and control groups from ladder test at 1 
and 3 months post-injury (6 animals per group were measured).  
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Figure 4-12. The analysis of paw slip frequency between treatment and control groups from ladder test 
at 1 and 3 months post-injury (n=6).  
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4.3 DISCUSSION 
 
 We have demonstrated that acute delivery of VEGF and PDGF significantly halts the 
secondary degeneration that normally occurs following the initial physical injury. In treated 
animals, the lesion cavities were significantly smaller at both 1 and 3 months post-injury when 
compared to controls. VEGF+PDGF treatment also reduced gliosis around the lesion cavity. 
Surprisingly, the delivery of VEGF and PDGF, which are well-known for their roles in 
promoting angiogenesis, did not promote blood vessel formation in our SCI model when 
compared to the lesion controls. On the other hand, we did observe a robust effect of treatment 
on the inflammatory response, as suggested by the changes in distributions of 
microglia/macrophages subtypes within the injured tissues. This highlights the complexity of 
the effects of VEGF and PDGF, especially when delivered together.  
 
Indeed, recent reports have demonstrated that combined VEGF/PDGF may have 
differing effects depending on the microenvironmental conditions as well as the timing and 
dose of the growth factors (Greenberg et al., 2008).  By using a chorioallantoic membrane 
model, it was shown that VEGF induces the formation of VEGF-R2/PDGF-Rβ complex, which 
suppressed pericyte function and blood vessel maturation. Additionally simultaneous delivery 
of VEGF and PDGF into an ischemic muscle injury model resulted in prolonged angiogenesis 
when compared with VEGF alone, although less total new vessel formation (Korpisalo, 2008).  
Another study by Chen et al. (2007) suggested that formation of blood vessels may require 
spatio-temporal delivery (VEGF followed by PDGF delivery) in a hindlimb ischemia model. 
Furthermore, the expression of major angiogenic receptors are concomitantly repressed 
following SCI causing the insufficient ligand/receptor binding for the delivered angiogenic 
factors (Hausmamn et al., 2011). Moreover, in our study, the dose of VEGF+PDGF was 
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significantly higher, with a sustained delivery period when compared to other studies, which 
might lead to different  downstream effects (Chen et al., 2007, Das et al., 2009, Gendron et al., 
1999, Hao et al., 2004). It was also shown that high concentration of VEGF induced 
inflammation rather than angiogenesis (Croll et al., 2004). Nevertheless, it should be noted that 
our quantification of  blood vessel density was measured at 200µm from the lesion edge which 
may not necessarily reflect the angiogenic response at the lesion epicentre. However, the 
rationale for this selection (as well as IBA1 positive cell quantification) is to allow us to 
compare the tissue at a consistent point/location due to the large difference in lesion size. Whilst 
selecting a different distant from the lesion epicentre would result in either analysing missing 
tissue (in controls) or normal tissue (in treatment). 
Despite not seeing any angiogenic effect from the combined delivery of VEGF and 
PDGF,  we did observe a robust effect of treatment on the inflammatory response, as evidenced 
by the accumulation of microgia/macrophages at the epicentre and the change in distribution of 
subtypes of these cells within the injured tissues. There were more phagocytic and fewer 
activated macrophages/microglia in treated animals at the lesion edge compared to controls. 
VEGF has been shown to promote the permeability of BSB and increase the monocyte 
infiltration (Heil et al., 2000, Kim et al., 2001, Miyamoto et al., 2000) whilst PDGF enhances 
monocyte-macrophage differentiation as well as the early phagocytic activity of monocytes 
(Bezuidenhout et al., 2007, Krettek et al., 2001). However.  neither growth factor is directly 
pro-inflammatory but in the presence of an inflammatory microenvironment they can exert 
immunomodulatory properties (Croll et al., 2004, Takahashi and Shibuya, 2005). In addition, 
both VEGF and PDGF have been shown to signal through a multitude of pathways including 
the activator of transcription of STAT3 in Janus Kinase/Signal Transducer and Activator of 
Transcription (JAK/STAT) (Bartoli et al., 2000, Ferrara and Davis-Smyth, 1997, Lewis, 2007, 
Vignais et al., 1996) and Mitogen Activated Protein (MAP) kinase signaling pathways 
 Page 84 
Yun Wai Young 2010 Page 84 
(Tchaikovski et al., 2008). The activation of STAT3 signaling in macrophages represses the 
functions of pro-inflammatory transcription factors such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and activates the anti-inflammatory pathways (Lang, 
2005, Murray, 2006). Also, both JAK/STAT and MAP pathways are involved in recognition 
and phagocytosis of apoptotic cells (Lemke and Rothlin, 2008), which is a significant driver of 
phenotypic switching in macrophages from pro- to anti-inflammatory and a key process in the 
self-regulation of inflammation (Fadok et al., 1998). This might explain why there were fewer 
activated and more phagocytic macrophages/microglia in VEGF+PDGF treated animals. 
Activated microglia/macrophages (also known as pro-inflammatory microglia/macrophages) 
release cytotoxic molecules and contribute to tissue destruction whilst phagocytic or anti-
inflammatory microglia/macrophages are known to resolve inflammation and promote axonal 
regrowth. The treatment of VEGF+PDGF promotes the extravasation of 
monocyte/macrophages, phagocytosis of apoptotic cells and tissue debris for 
macrophages/microglia as well as the switching from pro-inflammatory (M1) to anti-
inflammatory (M2) phenotype. 
 
Although IBA1positive cells accumulated within the lesion cavity in treated spinal 
cords, we found a reduced number of immune cells at the comparable location in the margin of 
the lesion when compared to controls  . This might indicate the  decline of inflammatory 
response. In normal wound healing, the macrophage levels are significantly reduced around the 
wound site at around three weeks after injury and this reduction of macrophages is essential for 
transition from the inflammatory phase to the healing phase (Newton et al., 2004). Therefore, 
the increased number of macrophages/microglia, especially activated macrophages, observed in 
controls at both 1 and 3 months post-injury suggests the extended period of inflammatory phase 
which leads to further tissue damage as well as glial scaring. 
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Without further investigation, we cannot certain the beneficial effects on the 
lesioned spinal cord was  resulted from synergy between VEGF and PDGF. However, 
delivery of VEGF alone after SCI  only resulted in glial cell proliferation with some tissue 
sparing (~5-20% over controls) (Kim et al., 2009, Widenfalk et al., 2003). This suggests 
that the massive reduction in lesion cavity size observed in this study is not due to VEGF 
alone. The role of PDGF in CNS is less clear but some studies have suggested its 
neuroprotective role during development (Ishii et al., 2006, Zhu et al., 2009) and PDGF 
promotes remyelination after dymyelinating lesion (Allamargot et al., 2001, Jean et al., 
2002). However, neuron-specific PDGF knock-out does not influence the astroglial and 
angiogenic reponse after hippocampus injury (Enge et al., 2003). The implantation of a 
Schwann cell implant containing PDGF diminished axonal regeneration but improved 
remyelination   (Olson et al., 2009) and PDGF plays a role in neuroregulation and plasticity 
after SCI  (Xiyang et al. (2009). It would seem likely that VEGF+PDGF exerts some 
neuroprotective effects, but it is doubtful that this could explain the combined effects of  
reduction in secondary degeneration and gliosis, changes in macrophage/microglia numbers 
and morphology, and the promotion of axonal growth (Saville et al., 2004, Storkebaum et 
al., 2004, Tian et al., 2007b, Wells et al., 2003).  
 
Surprisingly, although we observed that VEGF+PDGF treatment resulted in a 
significantly smaller lesion size, reduced gliosis, and axon growth into the lesion cavity, we did 
not detect improvements in behaviour. This highlights the complex nature of the relationship 
between spinal cord repair and improvements in motor function. Normally there is a 
spontaneous gain of hindlimb function in rats after hemisection due to recovery from spinal 
shock (Hiersemenzel et al., 2000), plasticity of spinal circuits (Dunlop et al., 2004) and short 
distance axonal sprouting that can reconnect motor neurons in a path that circumvents the defect 
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which we also observed (Bareyre et al., 2004, Weidner et al., 2001). A range of experimental 
treatments have demonstrated improvements in behaviour above this spontaneous recovery 
level by augmenting these effects (Kwon et al., 2010). However, the contribution of axon 
sprouting into the lesion cavity, as seen in our treatment, to behavioural recovery is less well 
studied as it has rarely been achieved. A range of factors including target innervation (Heffner 
and Heffner, 1990), synapse formation (Katz et al., 1996), ratio of inhibitory/excitatory 
synapses (Prange et al., 2004), re-myelination (Mandemakers and Barres, 2005) and supporting 
cells (Parpura et al., 1994) all contribute to proper transmission of signals. Furthermore, axon 
sprouting into the lesion cavity does not guarantee that there is axon growth into the injured 
spinal cord that might restore transmission past the lesion In addition, a recent report has 
demonstrated that spontaneous recovery can involve propriospinal (interneuron) relay 
connections which bypass the injury site and mediate the supraspinal control of stepping, even 
when there is irreversible interruption of long descending supraspinal pathway (Courtine et al., 
2008). Therefore, it might be reasonable to postulate that VEGF+PDGF treatment was not able 
to augment the already robust compensatory mechanisms after hemi-section injury but may 
potentially augment the effect of treatments that do.  
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4.4 CONCLUSION 
 
Here it was demonstrated that acute delivery of VEGF+PDGF reduced secondary 
degeneration and gliosis after hemi-section SCI injury. Although known for their 
angiogenic effects, the reduction of lesion cavity size was not due to promotion of 
angiogenesis by VEGF and PDGF although they significantly modified the inflammatory 
response. This was evident by the altered macrophage/microglia population within the 
injured spinal cord. 
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5Chapter 5: Comparison of the effects of 
different dose of VEGF+PDGF  
5.1 INTRODUCTION 
 
After SCI, the uncontrolled inflammatory response leads to secondary changes, gliosis 
and the formation of inhibitory glial scars which limit spontaneous neural regeneration and the 
effectiveness of regenerative therapies. Targeting the inflammatory response has been a major 
focus of SCI research but there has been mixed success in studies modulating inflammatory 
response (McDonald, 1999). In the previous chapter, we demonstrated a novel therapeutic 
intervention which modulated the inflammatory processes and reduced the effects of secondary 
degeneration by deliverying VEGF+PDGF. Nonetheless growth factors including VEGF and 
PDGF possess dose responsive effects (Smith and Tallquist, 2010, Yang et al., 2009, Yasuhara 
et al., 2005). It seems reasonable to investigate the effects of different doses of VEGF+PDGF in 
our SCI model as we only delivered the growth factors at one dose (i.e 5µg) using a hydrogel 
patch. A study by Widenfalk (2003) showed that higher doses of VEGF promote better 
functional recovery in SCI animal models. Also,  the effect of sustained delivery of VEGF or 
PDGF alone in SCI remained unclear. Therefore,  the aims of these experiments are firstly to 
investigate the effects of different doses of VEGF+PDGF on immunomodulation and lesion 
cavity size 1 month after spinal cord hemisection.  Also,  population of M2 macrophages will 
also been identified using IBA1 and NG2 co-staining method as described before (Kigerl et al., 
2009).In this study, two different doses of VEGF+PDGF (i.e. 5 µg and 15 µg) will be delivered 
using commercially available mini-osmotic pump which provide stable delivery profile over 7 
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days. Secondly, the effect of VEGF or PDGF alone on SCI will be assessed by using the same 
osmotic pump. 
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5.2 MATERIALS AND METHODS 
 
5.2.1 Drug delivery pump preparation 
 
The preparation procedure was carried out under sterile condition. In brief, each mini-
osmotic pump (Alzet Model 2001, 1µl/hr for 7 days) was weighed prior to loading and the 
pump was filled with either 5 (Low Dose) or 15 µg VEGF 165(High Dose) (Quantikine®, 
R & D system, Inc) and PDGF-BB (Quantikine®, R & D system, Inc) dissolved in 168 µl 
Phosphate buffer Saline (PBS) using a blunt-tipped 27 gauge filling tube provided by the 
manufacturer . For saline control group, osmotic pump was loaded with 168 µl PBS only. 
To investigate the effect on individual growth factors on SCI, either 15ug VEGF or 15ug 
PDGF was loaded into a mini-osmotic pump. The filled pump was weighed and the net 
weight of the growth factor solution loaded was recorded. A catheter (15cm long) was then 
connected to the pump and the pump was primed in 0.9% sterile saline solution at 37 °C 
overnight before implantation.  
 
5.2.2 In vitro quantification of VEGF+PDGF release from mini-osmotic pump 
 
The osmotic pumps (n=2) loaded with 5 or 15 µg doses of VEGF+PDGF were 
connected to intrathecal catheter and the pumps were soaked in 0.9% sterile saline. The tip of 
catheter was placed inside a conical tube containing 200 µg PBS and the solution was changed 
every 24 hours. The concentration of total growth factors released was quantified using 
MicroBCA protein assay kits (Thermo Scientific) according to the manufacturer’s instruction. 
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5.2.3 Animal Surgery 
 
Approval was gained from the Queensland University of Technology and the Griffith 
University animal ethics committees. In contrast to previous chapter, adult male Wistar Kyoto 
rats (an inbred sub-strain of Wistar) were used. This strain of rat is physiologically comparable 
to Wistar and has been used in many SCI studies (Wiesenfeld-Hallin, 1993 ). For surgery. 
animals were anesthetised intraperitoneal injection of 70 mg/Kg Zoletil 100 (Virbac Animal 
Health) and 15mg/Kg Xylazine (Troy Laboratories Pty Ltd). Complete laminectomies were 
performed at T10 and T12 and lateral hemisection as previously mentioned. Mini-osmotic 
pumps (Alzet) were implanted subcutaneously. Catheters that connected to the pumps were 
passed under the T11 lamina ipsilateral to the lateral hemisection. The tips of the catheter were 
carefully placed on top of the lesion site (Fig 5.1). The pumps and catheters were sutured to the 
muscle to keep them in place. The muscles and skins were closed. Control animals were 
subjected to spinal cord lesion only or lesion plus osmotic pump delivering PBS solution only. 
Each group had 6 animals.  
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Figure 5-1.The catheter connected to the pump was inserted into the subdural space under the lamina under 
T11 and the tips of the catheter were carefully placed on top of the lesion site  
 
5.2.4 Animal scarifice and Immunohistochemistry  
 
The animals (n=6) were sacrificed 1 month after injury with injection of 1.5 mL sodium 
pentobarbital. The spinal cord were harvested, processed and immuno-stained as described 
in section 3.2.2. To identify M2 macrophages, tissue section was co-stained  with IBA1 and 
NG2 antibodies as described (Kigerl et al., 2009). The antibodies used in this study is listed 
in table 5-1.  
Primary Antibody  Stain for   Company  Dilution 
Mouse anti‐ NF 200  Neurofilament  Chemicon  1/1000 
Rabbit anti‐GFAP  Astrocyte  Chemicon  1 /1000 
Rabbit anti‐IBA 1  Macrophage/Microglia Wako  1/ 500 
Mouse anti‐NG 2  M2 Macrophage  Millipore  1/400 
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Secondary Antobody  Company   Dilution 
Alexa Fluor ®488 labelled Donkey anti‐rabbit antibody  Molecular Probes  1/400 
Alexa Fluor ® 594 labelled Donkey anti‐rabbit antibody  Molecular Probes  1/200 
Table 5-1. Antibodies used in this chapter. 
 
5.2.5.  Quantification of lesion cavity size and IBA1-positive cells 
 
The lesion cavity sizes were measured as described in section 3.2.3 and the IBA1- 
positive cells were quantified as described in section 3.2.4. 
 
 
 
5.2.6.  Statistical Analysis 
 
All analyses were carried out using SigmaPlot 11.0 (Systat software Inc). ANOVAs 
were used for lesion cavity size measurements and microglia/macrophage populations. Post-hoc 
analysis was performed using Fisher‘s LSD test (α=0.05). 
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5.3 RESULTS 
5.3.1 In vitro quantification of growth factors released from mini-osmotic pump 
 
To validate the delivery profile of the mini-osmotic pump, we performed an in vitro 
release experiment with mini-osmotic pumps loaded with 5 µg (Low Dose) or 15 µg (High 
Dose)  VEGF and PDGF. Figure 5-2 shows that that mini-osmotic pump released the growth 
factors constantly and approximately 0.7 µg of protein released every 24 hours. Over 95% of 
VEGF+PDGF was released after 7 days. The in vivo release pattern is expected to approximate 
to the in vitro release profile (Bittner et al., 2000).  
 
Figure 5-2. In vitro quantification of growth factors released from mini-osmotic pump over 7 days. 
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5.3.2 Histology 
 
To evaluate the effect of the different doses of VEGF and PDGF, we performed lateral  
hemi-sections to the thoracic spinal cord at T10 level of Wistar Kyoto rats. Animals were 
randomised into High Dose pump group (pump loaded with 15µg of VEGF and 15 µg of 
PDGF with catheter placed at site of injury); Low Dose pump group (pump loaded with 5 of 
VEGF and 5 µg of PDGF attached with catheter); Saline Control group (pump containing PBS 
only) and lesion only control (no pump was implanted). At 1 month post-lesion, 5 animals from 
each group were sacrificed and lesion cavity areas were assessed using immunofluoresence. 
Figure 5-3 shows the dramatic histological differences between VEGF+PDGF treated group 
whilst significantly smaller lesion cavities were observed in both treatment groups. More 
NF200 was observed in the High Dose VEGF+PDGF treatment group compared to the Low 
Dose treatment group.  
 
 
Figure 5-3. Representative immunofluorescence images showing the lesion cavity after spinal cord 
hemisection and VEGF+PDGF treatment at High and Low doses. One month after injury, sections 
harvested from high dose VEGF+PDGF treated (A,D), low dose VEGF+PDGF treated (B,E) and lesion only 
control (C,F) animals were stained with GFAP and NF200. (bar=500µm) 
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5.3.3 Quantification of lesion cavity size  
 
The lesion cavity sizes were quantified in two ways (1) by defining the margin of 
axons using NF200 and (2) by the margin of astrocytes using GFAP antibody. Figure 5-4a 
shows the average lesion cavity size at 1 month based on NF 200 measurement. The lesion 
cavity of High Dose pump  was the smallest (0.0013 mm2). The average lesion cavity sizes 
of Low Dose pump, Saline Control and Lesion Control groups were 0.07 mm2, 0.6 mm2 and 
0.75 mm2 respectively. The lesion cavity size of High Dose delivery was significantly 
smaller than Low Dose pump, Saline Control and Lesion Control groups (High Dose vs 
Low Dose, p<0.001; High Dose vs Saline Control, p<0.001; High Dose vs Lesion Control, 
p<0.001). Significant differences were also detected between the low dose group and 
control groups (Low Dose vs Saline Control, p0.004; Low Dose vs Lesion Control, 
p=0.017).  
When defined by GFAP, the average lesion cavity sizes were 0.12 mm2 for High Dose 
pump, 0.28 mm2 for Low Dose pump, 0.34 mm2 for Saline Control and 0.36 mm2 for Lesion 
Control (Figure 5-4b). The lesion cavity size for High Dose pump treated animal was 
significantly smaller than Low Dose pump delivery as well as both VH and LC groups 
(High Dose vs Low Dose, p<0.009; High Dose vs Low Dose, p<0.001; High Dose vs Low 
Dose, p<0.001). No significant difference was detected between the Low Dose pump group 
and the controls. 
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 (a)  
 
(b) 
  
 
 
 
 
 
 
 
 
Figure 5-4 Measurement of the spinal cord lesion cavity size at one month with the margin defined by 
axons (anti- NF200; a) and by astrocytes (anti-GFAP; b). Data are presented as mean±SEM and statistical 
comparison were performed using ANOVA (P<0.05).  
 
NF 
GFAP 
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5.3.4 Macrophages/microglia response and quantification around the lesion margin 
 
Figure 5-a-c shows the representative immunofluoresence images, showing IBA1 at the 
lesion site in the injured spinal cord in treated and control animals. Both High Dose and Low 
Dose treatment groups promoted the accumulation of IBA1 positive cells at the centre of the 
lesion cavity whereas no IBA1-positive cells were observed in the lesion cavity in control 
groups. A closer examination of the lesion cavity found that more large and rounded phagocytes 
were observed in High Dose pump group whilst most of the IBA1 positive cells in Low Dose 
group exhibited large and slightly branched structure.  
 
To investigate the dose-dependent effects of VEGF+PDGF on macrophages/microglia, 
IBA1 positive cells were examined along the circumference from the edge of the lesion. Similar 
to previous chapters, we classified the IBA1-positive cells into three different subtypes (resting, 
primed/activated and phagocytic) according to their size and morphology. We then quantified 
the distribution of each phagocyte subtype along the lesion margin 200 μm from the edge of the 
GFAP-defined lesion (Figure 5-5 b). Overall, there was a statistically significantly difference 
between cell size distribution in the treatment groups (High Dose & Low Dose) and contol 
group (P<0.001). High and low dose treatment groups had significantly more phagocytic cells 
(p<0.001) with 18.6% and 19.3% phagocytic cells (Low Dose vs High Dose, repectively) in the 
total IBA1-positive cell population compared to 3.6 % in the controls. In both treatment groups 
(High Dose and Low Dose), there were significant reductions of IBA1 positive cells in their 
primed/activated stage when compared to controls (High Dose vs controls, P =0.008; Low Dose 
vs controls, P <0.001). When comparing the treatment groups, there were significantly more 
phagocytic (P=0.006) and less primed/activated (P<0.001) in High Dose group when compared 
to Low Dose treatment group.  
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To further investigate the effect of VEGF+PDGF on macrophages/microglia, we 
identified M2 macrophages/microglia by NG2/IBA1 co-staining as suggested by Kigerl et al 
(2009). At 1 month post-injury, a higher number of NG2/IBA1 positive cells was observed in 
High Dose pump treated animals when compared to Low Dose and Lesion Control groups. 
Some NG2/IBA1+ cells were observed in LD but only a few cells were detected in controls. 
High magnification images were also taken to ensure NG2 is colocalised with IBA1-positive 
cells (Figure 5-6).  
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(e)   
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Figure 5-5. Marked differences on macrophages/microglia response were detected in different doses of 
VEGF+PDGF delivery at 1 month post-injury. (a-c) Representative anti- ionized calcium binding adapter 
molecule 1 (IBA1) images taken from the lesion of spinal cord harvested from high dose VEGF+PDGF 
treated (a), low dose VEGF+PDGF treated (b) and lesion only controls (c) animals. The lesion edge as 
indicated by GFAP staining was outlined by dash line. High magnification image taken at epicentre suggested 
that distinct morphology of IBA1-positive cells.  (d) IBA1 positive cells were classified into 3 different 
subtypes based on their size and morphologies and density of each subtype was measured. Data are presented 
as mean±SEM and statistical comparison were performed using ANOVA (P<0.05). (c) Representative anti-
NG2 and anti-IBA1 immunofluoresence images taken from the lesion of spinal cord from High Dose, Low 
Dose and Lesion Control. 
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Figure 5-6 Confocal images of representative of IBA1+ cells at 260x (a-c) lesion control (d-f) VEGF alone (h-
j) PDGF alone (k-m) High dose VEGF+PDGF. (a,d,h,k) IBA1 (b,e,i,l) NG2 and (c,f,j,m) merged image of 
both imunoreactivities.  
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5.3.5 Delivery of single growth factors using osmotic pump  
 
The delivery of individual growth factor did not reduce the lesion cavity size (Figure 5-6 
a-f). Lesion cavity sizes were similar between the VEGF and PDGF treatment groups and the 
lesion control and no significant difference was detected (Figure 5-6g).  
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Figure 5-7 VEGF or PDGF alone did not reduce the lesion cavity size at 1 month post-injury. (a) 
Representative images of whole spinal cord stained for NF200 and GFAP harvested from lesion control (a,d), 
high dose VEGF(b,e) and PDGF(c,f) treated animals . (g) Lesion cavity size quantification. 
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5.4 DISCUSSION 
 
The data presented here provide new insights into the dose response of growth factors to 
SCI. We have demonstrated that VEGF+PDGF delivered into the injured spinal cord induces 
dose-dependent effects on lesion cavity size and macrophages/microglia responses after SCI. 
Compared to controls, significantly smaller lesion cavity sizes and more phagocytic 
macrophages/microglia were detected at both low and high dose VEGF+PDGF. There were 
more M2 macrophages present at the lesion site in high dose animals compared to low dose and 
control animals. Taken together, our findings indicate that high dose VEGF+PDGF promoted 
the resolution of inflammation and prevented secondary degeneration 
A previous study reported that a single dose of 4 µg VEGF resulted in functional 
improvement after ischemic spinal cord injury whereas 1 and 20 µg VEGF did not lead to any 
significant improvement (Widenfalk et. al. 2003). Delayed intraparenchymal application of 
VEGF (6 weeks after injury) exacerbated the secondary damages in spinal cord contusion 
model (Benton and Whittemore, 2003) . Therefore, the concentration, timing and duration of 
VEGF and PDGF delivered are crucial for any resultant effects. Based on the study carried out 
by Schechter et. al. (2009), blocking of monocyte infiltration using specific antibody from the 
second week onward had no effect on functional recovery. This suggests that the beneficial 
effect of infiltrating monocytes is restricted to the first week of the injury which overlaps with 
our delivery period (7 days). However, high dose delivery resulted in reduced lesion cavity size 
and more robust activation of monocytes/microglia when compared to low dose treatment. This 
may be because of the blood and cerebral spinal fluid at the lesion site diluted the growth 
factors and therefore, the higher dose VEGF+PDGF flow rate (at least 90 ng/hr) might be 
required to achieve better recovery (Bowes et al., 2000, Chan, 2008, Dunn et al., 2005). 
Macrophages/microglia are recognised as a heterogeneous population and there has been long 
standing debate regarding to their functional role in CNS injury (Geissmann et al., 2010). Until 
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recently, the distribution and population of the pro-inflammatory (M1) and anti-inflammatory 
(M2) macrophages/microglia were characterised in mice by co-expression of IBA1/CD 68 and 
IBA1/NG2 respectively (Kaluza, 1992, Kigerl et al., 2009, Smirkin et al., 2010). Despite many 
attempts in using CD 68 antibody, we failed to detect any cells that were colocalised with both 
IBA1 and CD 68 in injured rat spinal cord (See Appendix). This potentially suggests a species 
specific difference in macrophage expression of receptors during activation (Haley, 2003). On 
the other hand, we were able to detect M2 macrophages by using IBA/NG2 antibodies. In our 
study M2 macrophages, probably derived from infiltrating monocytes, were largely excluded 
from the lesion centre and located at the margin. Similar results were observed in both saline 
controls and lesion controls as well as other studies(Gensel et al., 2009, Kigerl et al., 2009, 
Shechter et al., 2009). However, in VEGF+PDGF treated animals, a higher number of large 
rounded phagocytic IBA1/NG2 positive cells were observed around the lesion site. These M2 
macrophages cells were believed to promote recovery and tissue sparing by secreting 
neurotrophic factors such as BDNF and induce an anti-inflammatory programme by releasing 
anti-inflammatory cytokines such as IL-10 and arginase-I (Bomstein et al., 2003, Boven et al., 
2006, Schwartz and Yoles, 2006).  
Although the functional differences between microglia and macrophages remain 
unknown, the beneficial macrophages are most likely derived from naïve monocytes. In CNS 
injury, microglial activation predominates over macrophage infiltration and the activated 
microglia exhibit neurotoxic characteristics such as secreting TNF-α and glutamate after 
engulfment of myelin debris (Deng et al., 2010, Guillemin and Brew, 2004, Loane and Byrnes, 
2010, Schilling et al., 2003). In addition, an increased number of resident microglia after 
conditional blocking of monocyte-derived macrophage infiltration using diphtheria toxin did 
not promote recovery after SCI, further suggesting that activated microglia do not have a role in 
the recovery process (Kettenmann et al., 1990, Shechter et al., 2009). Furthermore, the activity 
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of activated microglia is transient and lower when compared to peripheral-blood macrophages 
(Hailer et al., 1997). The distinctive role of activated microglia and the monocyte-derived 
macrophages maybe due to the different timing of activation when they encounter damaged 
tissues; resident microglia become rapidly activated after the insult whereas the infiltrated 
monocytes are activated during migrating to lesion site (Carson et al., 1998, Carson et al., 2004, 
van Zwam et al., 2010). Pre-activation of naïve monocyte has been shown to be crucial for their 
beneficial effects as well as supporting their anti-inflammatory role (Lazarov-Spiegler et al., 
1998, Rapalino et al., 1998).  
VEGF has neuroprotective effects and acute injection of VEGF enhances tissue sparing 
after SCI (Jin et al., 2002, Rosenstein and Krum, 2004, Storkebaum et al., 2004, Widenfalk et 
al., 2003). In contrast, in present study, no neuroprotective effects were observed after a high 
dose of VEGF. Our results are in line with a recent report in which repetitive intrathecal 
injection of VEGF (4 ug in total) for 7 days had no effect on tissue sparing or astrogliosis (Van 
Neerven et. al. (2010). This lack of neuroprotection might be attributed to the dose and timing 
of VEGF treatment. In fact, beneficial effects were only reported when VEGF (~4 ug) was 
injected acutely after injury (Benton and Whittemore, 2003, Liu et al., 2010a, Liu et al., 2010b, 
Patel et al., 2009, Wang et al., 2005, Widenfalk et al., 2003).  
Although PDGF is neuroprotective effect during development and promotes 
remyelination, its role in SCI remains largely unexplored (Allamargot et al., 2001, Lewis et al., 
2003, Yao, 2009). In the present study, PDGF alone was not neuroprotetive. Similar results 
were observed when PDGF-bb was delivered directly post-injury in an ischemic model of brain 
trauma (Iihara et al., 1997, Zhang et al., 2010). Consequently, we conclude that the beneficial 
effects observed after combined VEGF+PDGF treatment are not due to synergy of the 
neuroprotective effects of each growth factor applied alone. On the contrary, the combined 
treatment has revealed de novo effects not obvious by single growth factor treatments. 
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VEGF can promote the breakdown of blood brain barrier and increases monocyte 
extravasation preceding angiogenesis whereas PDGF enhances early activation and 
phagocytic activity of peripheral-blood monocytes (Bezuidenhout et al., 2007, 
Bezuidenhout et al., 2009, Liu et al., 2006, Miyamoto et al., 2000, Patel et al., 2009, 
Proescholdt et al., 1999). Notably, pre-activation of monocytes was crucial for their 
beneficial effects when encountering damaged CNS tissues (Rapalino et al., 1998). As such, 
it might be reasonable to postulate that VEGF enhances the infiltration of peripheral 
monocytes whilst PDGF helps to activate these monocytes to non-classical phenotype, 
probably en route to the injury site.  In addition, the delivery of VEGF+PDGF enhances the 
recognition and phagocytosis of apoptotic cells, which is a significant driver of phenotypic 
switching in macrophages from M1 to M2 phenoype (Tchaikovski et al., 2008, Vignais et 
al., 1996). Therefore, increasing tissue repairing macrophages derived from infiltrating 
monocytes are important in stopping the inflammatory response and also providing 
essential factors for tissue repairing (Arnold et al., 2007, Imai et al., 2008).  
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5.5 Conclusions 
 
Week-long delivery of VEGF+PDGF via a mini-osmotic pump significantly reduced 
secondary degeneration and promoted the infiltration and activation of peripheral macrophages 
which are critically required for spinal cord repair. No neuroprotective effects was observed 
when VEGF or PDGF were delivered singly suggesting that neuro-regeneration required the 
combined effects of both growth factors. The beneficial effects of VEGF+PDGF were dose-
dependent. These findings indicate that the therapeutic effects of VEGF+PDGF might require 
optimising, depending on dose, time of administration relative to the injury 
(acute/subacute/chronic) and the period of delivery. This study provides a new understanding of 
multifactorial effects of VEGF+PDGF and the importance of peripheral blood monocyte 
recruitment after CNS injury. 
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6Chapter 6: Effects of VEGF+PDGF on 
contusion SCI model 
6.1 Introduction 
 
In previous chapters, we have demonstrated that the acute delivery of VEGF+PDGF 
successfully eliminated secondary degeneration and reduced inflammation. However, these 
results were based on our lateral hemisection model. Although ascending sensory and motor 
fibers are completely cut in the hemisection model, most animals regain hindlimb function after 
about 2 weeks (Steward et al., 2003). The recovery is believed to be caused by the combined 
effects of sprouting of preserved contralateral spinal tract (Borgens et al., 1990, Murray, 1974, 
Weidner et al., 2001) and multi-synaptic pathways (Pettersson et al., 1997). Therefore, the 
hemisection model may not be ideal for assessing behavioural recovery after spinal cord injury 
(Arvanian et al., 2009) . In addition, hemisection is a relatively mild SCI model with reduced 
gliosis and axonal dieback as well as a less robust inflammatory response (Beattie et al., 2002a, 
Hausmann, 2003). More importantly, the efficacy of some treatments vary between different 
SCI models. For example, intraspinal administration of chondroitinase reduced 
glycosaminoglycans and promoted regeneration of corticospinal axonal regrowth in lateral 
hemisection but not after contusion (Iseda et al., 2008). As such, it is rational to extend our 
observations and evaluate the effect of VEGF+PDGF in another SCI model. 
In this chapter, we will use the spinal cord contusion model of  SCI. The contusion 
model is more clinically relevant because most injuries to the human spinal cord involves 
contusion and/or compression rather than transection (Akhtar et al., 2008). More importantly, a 
more widespread and robust inflammatory response is induced by contusion when compared to 
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hemisection (Alexander and Popovich, 2009). Therefore in these experiments, we will deliver 
VEGF+PDGF (15 µg of each) over 7 days into the contused spinal cord. The effects of the 
growth factors will be evaluated 1 month after injury.  
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6.2  Materials and methods 
 
6.2.1 Drug delivery pump preparation 
 
The preparation procedure was carried out in the sterile laminar flow hood. In brief, 
mini-osmotic pump (Alzet Model 2001, 1µl/hr for 7 days) was weighed prior to loading and 
the pump was filled with  either 15 ug VEGF 165 and PDGF-BB dissolved in 168 µl 
phosphate buffered saline (PBS) or PBS only (for saline control) using a blunt-tipped 27 
gauge filling tube provided by the manufacturer. The filled pump was weighed and the net 
weight of the growth factor solution loaded was recorded. A catheter (15cm long) was then 
connected to the pump and the pump was primed in 0.9% sterile saline solution at 37 °C 
overnight before the pump implantation.  
 
6.2.2 Animal Surgery  
Young adult Wistar rats were anesthetised as previously mentioned. Spinal cord 
contusion injury was performed using a commercially available Infinite Horizon spinal cord 
injury device (Precision Systems & instrumental, USA) (Fig 6-1). In brief, complete 
laminectomy was performed at T10 and the exposed vertebral column was stabilised by 
clamping the T9 and T11 vertebral column with stabilising forceps. The impacting tip (2.5mm 
diameter) was lowered to within a few mm of the exposed cord and the tip was realigned to 
make sure the impact tip is pointed at the middle of the cord. The impact tip was raised 4-5mm 
above the exposed cord and the injury was made at 150 K dyne. After the injury, the animal 
was randomly assigned to one of the three different groups: treatment group (implantation of 
osmotic pump loaded with 15ug VEGF and PDGF); Saline Control group (implantation of 
osmotic pump loaded with only PBS) and lesion only control. Each group had 6 animals 
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Figure 6-1 The Infinite Horizon spinal cord injury device.  
 
 
6.2.3 Impact data analysis 
 
Data including actual impact force, displacement and velocity were recorded (Figure 6-
2) and compared to ensure there was no significant difference between each impact.  
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Figure 6-2 Captured screen from the Infinite Horizon spinal cord injury device software showing the 
actual force, displacement and velocity of each impact. The data were recorded and compared using 
ANOVA. 
 
 
6.2.4 Animal sacrifice and immunohistochemistry  
 
The animals were sacrificed 1 month post injury and the spinal cord was dissected 
and processed as described in section 3.2.2. The spinal cords were then immunostained with 
antibodies ( table 6-1) with the procedure as described previously in section 3.2.2.  
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Primary Antibody  Stain for   Company  Dilution
Mouse anti‐NF 200  Neurofilament  Chemicon  1/1000 
Rabbit anti‐GFAP  Astrocyte  Chemicon  1 /1000 
Rabbit anti‐ IBA 1  Macrophage/Microglia Wako  1/ 500 
Mouse anti‐NG2  M2 Macrophage  Millipore  1/400 
 
Secondary Antobody  Company   Dilution
Alexa Fluor ®488 labelled Donkey anti‐rabbit antibody  Molecular Probes  1/400 
Alexa Fluor ® 594 labelled Donkey anti‐rabbit antibody  Molecular Probes  1/200 
Table 6-1. Antibodies used in the contusion study. 
 
6.2.5Quantification of lesion cavity size 
 
The method of lesion cavity size quantification is described in section 3.2.3. 
 
6.2.6 Basso, Beattie, Bresnahan locomotor rating scale (BBB) 
 
The functional recovery of hindlimb movement was evaluated using BBB score (Basso 
et al., 1995). The recordings were performed independently by two trained observers who were 
blinded to the experimental groupings. Animals were placed on a circular arena with a non-
slippery floor and, during the course of 5 min, the hindlimb locomotion was graded from 0 (no 
observable hindlimb movement) to 21 (normal movement with parallel paw placement) (Table 
6-1). 
 
6.2.7. DigiGait Analysis 
 
Gait analysis was performed using Digigait system (Mouse Specifics, Inc., Boston, 
USA). Animals were placed on a motorised treadmill and the dynamics of paw and stride 
movement were captured from underneath through the clear treadmill belt with a high-speed 
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video camera (80 Hz). Animals were allowed to walk at 25cm/s. Video clips with 
approximately 1000 frames (~30 sec) were selected for analysis using the DigiGait imaging 
software. Rats were trained and recorded before contusion injury. The analysis of paw 
separation between left and right hindlimb and stepping rate (number of stride per second) was 
carried out pre-lesion and at 28 days after injury. 
 
 
Figure 6-3 The paw separation (A) and stepping rate (number of stride per second; B) were analysed 
using DigiGait imaging software at pre-lesion and at 28 days after injury 
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6.2.7 Statistical Analysis 
 
 
All analyses were carried out using SigmaPlot 9.0 (Systat software Inc). ANOVAs 
were used for impact data and lesion cavity size measurements with post-hoc analysis of 
significant differences performed using the Fisher LSD (α=0.05). BBB scores and Digigait 
were analysed by ANOVA.  
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6.3  RESULTS 
 
6.3.1 Impact data analysis 
 
The impact data of each impact were recorded and compared to ensure the injuries 
created are reproducible. By using ANOVA, we did not detect any significant difference 
between the VEGF+PDGF treatment, saline control and lesion control in actual impact force 
created (Figure 6-4a), displacement (Figure 6-4b) and velocity (Figure 6-4c). 
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Figure 6-4 Comparison of impact data including actual force created (A), displacement (B) and (C) 
between the VEGF+PDGF treated, saline control and lesion only control animals. No significant 
difference was detected in any of these comparisons. Data are presented as mean±SEM and statistical 
comparisons were performed using ANOVA (P<0.05)  
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6.3.2 Histology 
 
To evaluate the effect of VEGF+PDGF on spinal cord contusion injury, we performed 
immunofluoresence staining 1 month after injury. significant smaller lesion cavity was 
observed in VEGF+PDGF treated animals as suggested by NF 200 and GFAP staining when 
compared to the control animals (Figure 6-5).  
 
 
 
 
Figure 6-5  Acute delivery of VEGF and PDGF reduced secondary degeneration after spinal cord 
contusion injury. a-b: Representative image showing the lesion site (indicated by box) of treated animals and 
control animals immunoreactive for  NF200 (a) and GFAP (b).  c-d: Representative image showing the lesion 
site (indicated by box) of control animals stained with NF 200 (c) and GFAP (d). The central canals are 
indicated by arrows 
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6.3.3 Lesion cavity size quantification 
 
At 1 month, the lesion cavity sizes were quantified in two ways: by defining the margin 
of axons using NF200 immunoreactivity and by the margin of astrocytes using GFAP 
immunoreactivity. The lesion cavity size of the treatment group was significantly smaller than 
Saline Control and lesion control (For NF200: treatment vs Saline Control, p=0.017; treatment 
vs lesion control, p=0.025. For GFAP: treatment vs Saline Control, p=0.017; treatment vs lesion 
control, p=0.025). No difference was detected between the two control groups (Figure 6-6).  
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Figure 6-6. Measurement of the spinal cord lesion cavity size at one month with the lesion margin 
defined by NF200 immunoreactivity (top) and by GFAP immunoreactivity (bottom). Data are presented 
as mean±SEM and statistical comparisons were performed using ANOVA (P<0.05). 
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6.3.4 Immunolabelling of M2 macropahges/microglia 
 
To investigate the effects of VEGF+PDGF on macrophages/microglia in contusion 
model, IBA1 positive cells were examined along the circumference from the edge of the lesion. 
A closer examination of the lesion cavity found that more large and rounded phagocytes were 
observed in VEGF+PDGF treatment group(Figure 6-7 D) whilst most of the IBA1 positive 
cells in saline control and lesion only control exhibited large and slightly branched structure 
(Figure 6-7E-F) 
 
To further identify the M2 macrophages/microglia subtypes, the sections were co-
immunostained with IBA1/NG2. At the lesion centre, more M2 macrophages were detected at 
the lesion cavity of VEGF+PDGF treated animals when compared to controls. (Figure 6-8). 
This suggests that the delivery VEGF and PDGF promote the switching of macrophage 
phenotypes and thus resolve the inflammatory environment. 
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Figure 6-7. Marked differences on macrophages/microglia response were detected between the 
VEGF+PDGF treated and control animals. (A-C) Representative anti- ionized calcium binding adapter 
molecule 1 (IBA1) images taken from the lesion of spinal cord harvested from VEGF+PDGF treated (a), 
Saline control (b) and lesion only controls (c) animals. Higher magnification image taken at epicentre 
suggested that more large and rounded phagocytes was observed in VEGF+PDGF treated animals (D) whilst 
most of the IBA1 positive cells in saline control (E) and lesion control (F) exhibited large and  slightly 
branched structure. 
 
 
Figure 6-8. High magnification images at lesion site show NG2 and IBA1 co-immunostained in 
treatment (A-C) and control animals (D-F). Higher numbers of NG2/IBA1 positive cells were observed in 
VEGF+PDGF treated animals. (Bar=100µm) 
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6.3.5 Digigait Analysis 
 
Figure 6-9A shown the progressive paw stepping of an un-lesioned rat. Figure 6-8B 
shows paw separation, pre-lesion and in control and treated rats. At day 28, significantly wider 
paw separation was detected between left and right hindlimb in control when compared to pre-
lesion and treatment rats (pre-lesion vs control, p<0.001; VEGF+PDGF treated vs control, 
p<0.001). At 28 days after injury the control animals had a significantly higher frequency of 
stepping than pre-lesion and VEGF+PDGF treated rats (p<0.001). No significant difference was 
observed between the pre-lesion and VEGF+PDGF treated rats in either paw separation and 
stepping frequency.  
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Figure 6-9 VEGF+PDGF treatment restored paw placement and step frequency to prelesion levels. A: 
Sequential images of unlesioned rat on the treadmill with paw placement identified by Digigait software. B: 
Analysis of paw separation as a measurement of hindlimb base of support. C: Analysis of stepping frequency. 
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6.3.6 Open-field locomotion analysis 
 
Open field locomotion was scored using the BBB locomotion open field score at day 
1, 7, 14, 21 and 28 post-injury demonstrated that VEGF+PDGF treated animals (AP) had 
higher BBB score when compared to Saline Control (VC) and lesion control (LC) groups 
(Figure 6-10). Significantly enhanced recovery was detected in treatment group at day 14, 
21 and 28 (Day 14: AP vs VC, p=0.007; AP vs LC, p=0.014; Day 21: AP vs VC, p=0.002; 
AP vs LC, p=0.005; Day 28: AP vs VC, p=0.007; AP vs LC, p=0.017). No significant 
difference was observed between the two control groups. 
 
Figure 6-10. VEGF+PDGF promoted recovery of functional recovery. The BBB score was determined at the 
indicated time-point after injury and significant enhanced recovery was detected in treatment groups (AP) 
when compared to Saline Control (VC) and lesion control (LC) at day 14, 21 and 28 as indicated by * (Day 
14: Active Pump AP vs VC, p=0.007; AP vs LC, p=0.014; Day 21: AP vs VC, p=0.002; AP vs LC, p=0.005; 
Day 28: AP vs VC, p=0.007; AP vs LC, p=0.017). Data is presented as mean ± SEM (6 rats in each group).
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6.4. Discussion 
 
The aim of this chapter was to examine the effect of VEGF and PDGF delivered over 7 
days into a spinal cord contusion injury. Consistent with our previous findings, the growth 
factors resulted in significant reduction in lesion cavity size. In addition, a robust anti-
inflammatory macrophages/microglia response was observed, with more large, rounded 
phagocytes at the center of the lesion cavity. Importantly, VEGF+PDGF treatment improved 
functional recovery after spinal cord contusion injury. Given the prevention of secondary 
degeneration by this treatment, improvement in functional recovery probably reflects better 
preservation of axon tracts, rather than regeneration. This further confirms our hypothesis that 
VEGF+PDGF have a immunomodulatory role in promoting the transition of 
macrophages/microglia from pro- to anti-inflammatory types even in a SCI model with a robust 
inflammatory response (Akhtar et al., 2008).  
There are several rat models that have been extensively used in studing SCI including 
transection, contusion as well as ischemia models (Beattie et al., 2002b, Qayumi et al., 
1997, Talac et al., 2004). Different models have been used to assess different aspects of the 
injury: for example, transection models have been used to evaluate strategies that target 
axonal regeneration. The anatomic continuity of regenerated axons can be easily assessed 
by microscopy or by injection of fluorescently labelled dyes such as dextran (Carr et al., 
1994). Lateral hemiection is one of most commonly used transection models. In this model, 
the integrity and function of tissue of one side of spinal cord is preserved which allow 
comparison between injured and intact tissues (Akhtar et al., 2008). The bladder function is 
also maintained, resulting in less labour-intensive post-operational animal care (Xu et al., 
2003). However, one of the major drawbacks is difficulty in the interpretation of behaviour 
analysis due to possible re-connection of the circuit (from the brain to central pattern 
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generator) at the contralateral side of the injury (Mills et al., 2001, Talac et al., 2004). On 
the other hand, contusion injuries are most commonly seen in human SCI and therefore, 
contusion models in animals are believed to be more clinically relevant (Xu et al., 2003). 
One advantage of this model is that the injury can be induced by a computer controlled 
impactor, and therefore a more precise, controlled injury can be created when compared to 
other models (Gruner, 1992). In addition, a more valid behaviour analysis can be carried out 
in contusion model due to less variation of the injury created when compared to other injury 
models (Sedy et al., 2008). 
Despite SCI animal models being long established, the translation of treatments from 
one model to another, or even from animals to humans, has been problematic. For example, 
administration of anti-CD11d integrin monoclonal antibody, which limits the trafficking of 
leukocytes and macrophages into injured site was neuroprotective in contusion injury (Gris 
et al., 2009, Utagawa et al., 2008) but not in severe clip compression injury (Hurtado et al., 
2010). Intraspinal injection of high dose chondroitinase reduced glycosaminoglycan and 
promoted corticospinal tract regrowth in spinal cord hemisection model but not in contusion 
injury (Iseda et al., 2008). This was attributed to anatomical and physiological differences 
including inflammatory responses after SCI in different models (Akhtar et al., 2008). It has 
been demonstrated that contusion injury resulted in widespread and robust macrophage 
response extending several millimetres rostral and caudal to the injury whilst localised 
inflammatory responses were observed in transection injury (Siegenthaler et al., 2007). 
Also, in the same study, contusion injury resulted in widespread tissue degeneration and 
white matter demyelination which were absent after hemisection.  As such, vigorous testing 
in different animal SCI models seems to be crucial before human clinical trial especially for 
inflammation-modulating therapy. 
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 The present study highlights the fact that pro-inflammatory macrophages/microglia 
were mainly distributed throughout the epicentre of the lesion and at its margins while anti-
inflammatory macrophages/microglia were largely excluded from the lesion in contusion 
injury. In contrast, animals treated with growth factors resulted in more anti-inflammatory 
phagocytes located at the lesion centre. As seen in other models, these tissue-repairing 
macrophages are crucial in terminating inflammatory response and some growth factors 
needed for ongoing repair process as well as eliminating glial scar associated matrix 
proteins which subsequently promote functional recovery (Nahrendorf et al., 2007, 
Schwartz, 2010, Shechter et al., 2009). As a result, it appears that the local activated 
microglia/macrophages failed to provide such terminating signals and resulted in an 
unresolved inflammatory response. The requirement of blood-derived or resident 
monocytes are crucial in resolving inflammation as well as initiating repair process(David 
and Kroner, 2011, Pruss et al., 2011). 
Although we have demonstrated that 15 µg VEGF and 15 µg PDGF treatment results in 
significantly smaller lesion cavity size in both hemisection and contusion injury, the optimal 
dose, timing and delivery rate of growth factors might be greater in contusion injury because of 
the more widespread pathology and larger lesion cavity when compared to hemisection 
(Siegenthaler et al., 2007).  However, this is a preliminary study and different delivery regimes 
of growth factors should be optimised in future experiments.  
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 6.5 CONCLUSION 
 
The delivery of VEGF+PDGF, via a mini-osmotic pump, reduced the lesion cavity size 
and promoted functional recovery in contusion injury model. Consistent with previous studies, 
growth factor treatment increased the population of  anti-inflammatory macrophages in 
contusion injury as occurred after hemisection. We hypothesised that the delivery of growth 
factors increased the infiltration of resident/blood- derived monocytes which transform into M2 
macrophages and initiates the “inflammatory resolving” and tissue repairing phase.  
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Chapter 7: General Discussion and future 
directions 
7.1 GENERAL DISCUSSION 
 
It is commonly accepted that the secondary degeneration is caused by prolonged 
inflammation after spinal cord injury. As such, modulation of the inflammatory response 
becomes an attractive therapeutic approach. In an effort to halt the unregulated inflammation, 
different drugs or molecules that target various aspects of inflammation, such as 
methylprenisolone, have been developed and validated in SCI animal models. Despite 
successful in stopping the secondary degeneration and preserving neuronal cell death, large 
scale nerve regeneration is rarely reported. Indeed, inflammation evoked after injury within 
CNS plays a major role in repair and this process seems to be insufficient and not optimally 
controlled (Crutcher et al., 2006, Yoles et al., 2001). A very strong boost of inflammation (T-
cells) has been shown to exacerbate the injury whereas no effects were observed when few of 
these cells were injected (Fisher et al., 2001, Moalem et al., 1999a, Moalem et al., 1999b). 
Therefore, only a very controlled boosting of inflammatory response may be of benefit to the 
spinal cord following injury. In addition, the inflammatory response is a complex process 
involving many cell types and increasing the population of the wrong cell types might also 
cause further destruction (Gensel et al., 2009). Recently, it was demonstrated that blood-derived 
macrophages, which are reminiscent of alternatively activated or tissue-repairing M2 
macrophages, are not spontaneously recruited to the injured spinal cord (Boven et al., 2006, 
Schwartz, 2003, Schwartz et al., 1995). So the rationale for this project was to increase the 
extravasation of the peripheral-monocytes/macrophages, through the synergistic action of 
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VEGF and PDGF. The increased recruitment of macrophages is believed to promote the 
phagocytosis of apoptotic cells and debris which enhance the transition from M1 to M2 
macrophages, and thus helping resolve the inflammatory response and initiating repair process.  
 
To justify this hypothesis, we first performed a study in which the infiltration of blood-
derived macrophages was reduced using hyperbaric oxygen treatment (HBOT) (Chapter 3). Our 
results revealed that HBOT has no effects on lesion cavity size after spinal cord hemisection 
even though the total number of macrophages/microglia was significantly reduced. We further 
classified the local macrophages/microglia into 3 different subtypes based on their sizes and 
morphologies, as indicative of their activation stages. Fewer activated and primed subtypes 
were detected in treated animals, which suggests that HBOT indeed suppressed the macrophage 
activation and thus the damaged cells and oxidised extracellular matrix proteins remained in 
situ and inflammatory response remains unresolved . Similar effects were seen in other studies 
where both neutrophil and macrophage recruitment was reduced in animal models of ischemic 
and ischemic/reperfusion brain injuries (Larson et al., 2000, Miljkovic-Lolic et al., 2003). This 
might explain why no large scale axonal regrowth is seen in anti-inflammatory therapies and 
the therapeutic effects are due to sparing of pre-existing neural pathways while leaving the 
inflammatory response unresolved (Alexander and Popovich, 2009). Therefore, anti-
inflammatory treatments may form a useful “stopgap” treatment that provides some functional 
improvement but based on the histological outcomes, the residual damage suggests that this 
approach may not form the basis of truly regenerative strategy. 
As pointed out in a review by Schwartz (2010), boosting the extravasation of naïve 
monocytes enable them to spontaneously locate to the lesion site and correctly differentiate into 
M2 subtypes. However, as mentioned before, the timing, location and level of boosting have to 
be carefully controlled in order to have beneficial effects. To achieve this, we delivered the 
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growth factors using a hydrogel-based polymer which is known to release 80% of incorporated 
proteins within 48 hours (Chapter 4) . The relatively short period of VEGF+PDGF delivery 
resulted in significantly smaller wound cavities and reduced gliosis, and the lesion cavities were 
filled with axon and macrophages/microglia. Analysis of the macrophages/microglia 
surrounding the lesion revealed that the growth factors modulated the immune response 
resulting in altered macrophage/microglia morphology (more phagocytic and fewer activated) 
in treatment group when compared to controls. In addition, the total number of phagocytes was 
reduced in treated animals further suggesting that the growth factors promote the switching 
from pro- to anti-inflammatory phase. Despite the histological improvement, no behavioural 
improvement was detected which highlights the complex relationship between spinal cord 
injury/repair and motor functional improvement. Whilst promoting axonal growth across a 
defect is important it does not per se guarantee functional signalling and a range of factors 
including target innervation (Kingwell, 2010), synapse formation (Dumont et al., 2001a) and 
remyelination (Franklin, 2003, McGavern et al., 1999) also play a important role in proper 
transmission of signals. In addition, several questions have arisen as a result of the study. 
Firstly, are the observed beneficial effects attributable to single growth factors or by the syngery 
of both growth factors? Secondly, how is the inflammatory reponse affected by different doses 
of growth factors? Also, we cannot conclusively determine the microgia/macrophage phenotype 
by judging their size and morphology only. Additional experiments have to be carried out to 
identify definitively the M1 and M2 populations.  
To answer the questions above, we altered the doses of growth factors delivered into the 
injured spinal cord using a commercially available pump over a 7 day delivery period (Chapter 
5). Delivering a higher dose of VEGF+PDGF into injured lead to significantly smaller lesion 
cavity size and more phagocytic macrophages/microglia at the lesion edge when compared to 
lower dose of growth factors and controls. Immunlabelling of M2 phagocytes using distinct 
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markers further confirmed that the phagoctytic cells were indeed M2 macrophages/microglia. 
This reinforces our hypothesis that VEGF+PDGF promotes the resolution of inflammation and 
neuro-repair by enhancing the switching from M1 to M2 macrophages. At the same time, no 
reduction of lesion size was detected when a high dose of VEGF or PDGF was delivered into 
injured spinal cord. This suggests that the improvement is not due to the neuroprotective effect 
but the syngery effect of both growth factors. The mechanism lying behind these observations 
remains elusive. We hypothise that the growth factors increase the influx of peripheral 
monocytes/macrophages and target the receptor tyrosine kinases expressed on these 
macrophages and signal through a multitude of pathways including both JAK/STAT, MAPK 
and phosphatidylinositol 3 kinase (PI3K)  signalling pathway (Tchaikovski et al., 2008, Vignais 
et al., 1996, Yamauchi et al., 2006).  Indeed, VEGF activates MAPK (Doanes et al., 1999) and 
PI3K pathway (Abid et al., 2004) while PDGF  stimulates the activation of STAT1 pathway 
(Ramana et al., 2001, Sarkis et al., 2006). The activation of both STAT1 and MAPK as well as 
PI3k pathway is crucial in upregulation of TAM system (Binder and Kilpatrick, 2009, Linger et 
al., 2008).   The activation of TAM signalling plays a major role not only in promoting the 
phagocytosis of apoptotic neutrophils by M1 macrophages (Rothlin and Lemke, 2010, Ye et al., 
2011) but also provide an intrinsic feedback inhibitor of  Toll-like receptor  and cytokine-driven 
immune response through the expression of  suppressor of cytokine signalling (SOCS) proteins 
(SOCS1 and SOCS 3)  (Rothlin et al., 2007, Rothlin and Lemke, 2010). The expression of the 
SOCS proteins induces the conversion of M1 to M2 macrophages and release anti-
inflammatory and reparative cytokines such as TGF-β1 and IL-6 (Mandal et al., 2011).  IL-6 
activates JAK1 and JAK2 leading to STAT3 tyrosine phosphorylation and STAT1 
sequestration which resulted in pro-resolution of inflammatory response  (Aaronson and 
Horvath, 2002).  In injured spinal cord, the immune response is unrestrained resulting in 
chronic inflammation which might possibly due to (1)low magnitude of STAT1 activation ; (2) 
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insufficient peripheral monocytes for phagocytosis and (3) the lack of regulatory signalling for 
inflammation (Alexander and Popovich, 2009, Beck et al., 2010).  
Despite the fact that SCI animal models have been widely used in preclinical testing , 
discrepancies still exist between animal studies and clinical trials. This barrier might be 
attributed to differences in injury type as well as inflammatory response induced between SCI 
animal model and clinical SCI (Akhtar et al., 2008, Bouyer, 2005, Siegenthaler et al., 2007). 
Therefore, we next examined the effect of VEGF+PDGF on contusion model, which is a more 
clinically relevant model than hemiseciton. Similar to the hemisection model, high dose growth 
factor delivery into the contusion injury, using 7 day osmotic pump, resulted in significantly 
smaller lesion cavity size and more phagocytic (M2) macrophages at the lesion centre. The 
effects of different concentrations of growth factors delivered should be further investigated in 
the future because of larger lesion cavity size in the contusion model and more robust 
inflammatory response indicates that the growth factors may not have reached all regions of the 
damaged spinal cord (Siegenthaler et al., 2007).  
Altogether, this study sheds a new light on the beneficial role of VEGF+PDGF 
treatment for SCI. To our knowledge, this is the first study that demonstrates that VEGF+PDGF 
prevents secondary degeneration and alters the inflammatory environment of the injured spinal 
cord. Importantly, the microenvironment created by anti-inflammatory macrophages is the link 
between inflammation and tissue repair. The provision of such a microenvironment may 
provide a significantly better target for secondary therapies, including delivery of neural growth 
factors, neural cells and stem cells (Lutton and Goss, 2008). Therefore, acute delivery of VEGF 
and PDGF is potentially new therapy to reduce secondary degeneration and provide a platform 
for repair in acute spinal cord injuries. 
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7.2 FUTURE DIRECTIONS 
 
The present study raises many questions and opens new veins of research in the 
laboratory; the primary question being how VEGF+PDGF affects the early inflammatory 
response following SCI. (Schwartz, 2010)Therefore, future studies will examine the effects of 
VEGF+PDGF on macrophages using specific markers such as IBA1 at early time-points (i.e 
during first week after injury) (Leskovar et al., 2000). In addition to immunofluoresence, DNA 
microarray could be employed to study gene expression involved in inflammatory responses 
and neuroprotection after treatment (Bareyre and Schwab, 2003, Mandel et al., 2003). Also, to 
prove our hypothesis, real-time polymerase chain reaction will be used to study the interaction 
of VEGF+PDGF with multiple pathways including both Janus Kinase/Signal Transducer and 
activator of Transcription (JAK/STAT) and Mitogen Activated protein (MAP) kinase signalling 
pathways. Also, activation of the STAT signalling pathway will be detected using 
immunhistochemistry and western blot with antibodies targeting phosphorylated receptors 
(Yamauchi et al., 2006).  Also, blocking of STAT1 signalling pathway using curcumin  will be 
useful in confirming the interaction between STAT pathway and VEGF+PDGF (Kim et al., 
2003a, Wang et al., 2009). 
 
Although the high dose VEGF+PDGF significantly reduced the lesion cavity size in 
contusion injury, several experiments will be necessary to address several issues. First of all, 
different therapeutic doses or different ratio of growth factors should be tested in this SCI 
model. Higher concentrations of growth factors might be favourable as the lesion cavity in 
contusion is larger than the one in hemisection. Secondly, anterograde tracing techniques could 
also be applied to see if any re-inneveration of cortico-spinal tract occurs after treatment 
(Shubayev and Myers, 2002). Electrophysiology would be useful to determine if there is 
synaptic reconnection in the injured cord. Thirdly, examination of remyelination using myelin 
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stains such as Luxol fast blue, would be an exciting research focus (Sicotte et al., 2003). 
Fourthly, additional analysis such as inter-rater reliability tests should be carried out o ensure 
consistency for macrophage activation analysis.  Last but not least, secondary treatments such 
as stem cells or olfactory ensheathing cells transplantation or neurotrophin delivery could be 
applied after intial VEGF+PDGF treatment to see if there are any significant functional 
improvements after combined therapies.  
Importantly however, activation of microglia and macrophages can cause chronic pain 
after SCI (Elliott et al., 2009, Hains and Waxman, 2006, Liu et al., 2010a). Therefore, it will be 
necessary to assess the nociceptive thresholds with paw withdrawal, before moving to human 
clinical trial (Bruce et al., 2002, Detloff et al., 2008).  
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7.3 CONCLUSIONS 
 
The studies presented in this thesis have suggested that promoting the infiltration of 
blood-derived monocytes/macrophages, by acute delivery of VEGF and PDGF, significantly 
reduced the secondary degeneration and promoted axonal growth into the defect site in both 
hemisection and contusion SCI models. The observed immunomodulation effect was caused by 
the combined effect of both growth factors as single growth factor delivery has no effect on 
microglia/macrophages population. The higher number of M2 macrophages macrophages 
observed at the lesion centre in treatment group when compared to controls suggests that the 
growth factors promoted transition from a pro- to an anti-inflammatory response, and thereby 
enhanced recovery. In addition, hyperbaric oxygen treatments, which reduced 
macrophages/microglia at the lesion site, had no histological improvement. This further 
suggests the important role of monocyte/macrophages in resolving inflammatory environment 
after phagocytosis. Taken together, this study has increased our knowledge of the inflammatory 
response after SCI and its modulation by VEGF+PDGF. The results suggest an interesting 
avenue for future clinical treatments and may provide a platform to improve the efficacy of  
other  treatments.  
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Appendices 
Appendix 1.1 No distinct morphological difference of IBA1 positive cells between grey 
and white matter 
 
 
Figure A-1. No Significant morphological difference of IBA1 positive cells between grey and white 
matter after hemisection injury. (A) Representative glial fibrillary acid protein image taken from 
hemisectioned spinal cord. (B) High magnification anti-ionized calcium binding adapter molecule 1 (IBA1) 
image taken from white matter.(C) High magnification IBA1 image taken from grey matter. 
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Appendix 1.2: Histological images of CD 68 staining showing unspecific reactivity 
 
 
Figure A-2. Histological image showing unspecific reactivity of antibody CD 68 in spinal cord injury 
rat model. (A-C) Representative anti-ionized calcium binding adapter molecule 1 (A) and CD 68 (B) 
image taken from the lesion cavity of spinal cord injury model (hemisection). (C) Merged image of both 
immunoreactivities. 
